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Liver fibrosis is the accumulation of extracellular matrix proteins in response to 
hepatocellular injury.  Worldwide, liver fibrosis and cirrhosis accounts for nearly 
160,000 deaths per year.  It results from many different etiologies, including excessive 
alcohol consumption, viral infections and obesity.  Our group has a vested interest in the 
molecular mechanisms that underlie this disease.  Many patients on a solid organ 
transplant waiting list have excessive fibrosis, and those who receive a transplant often 
develop complications associated with recurrent fibrosis.   
One of the main objectives of our lab is to identify novel biomarkers of liver 
fibrosis, which will open avenues to understand novel mechanisms.  Using this 
approach, we also test and develop therapeutic options to ameliorate liver fibrosis.  This 
thesis focuses on identifying and understanding microRNA (miRNA) changes during 
fibrotic conditions. miRNAs are small, single-stranded RNA molecules that negatively 
regulate protein translation.  In the following studies, we systematically examine 
changes in miRNA expression during liver fibrosis and identify two novel mechanisms 
that have cell-specific expression and function in the liver during liver fibrosis.   
In our first study, we describe a family of miRNAs that is upregulated during 
human and rodent liver fibrosis.  This group of miRNAs, the miR-214/199 family, has 
five specific unique mature sequences that have been reported to regulate a variety of 
different targets.  In the liver, expression of this family is focused predominantly in 
nonparenchymal cells.  One member of this miRNA family, miR-214-5p, regulates 
expression of Twist1, a mesenchymal transcription factor that promotes expression of 
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this family.  Using in vitro techniques, we characterize this novel negative feedback 
loop in activated hepatic stellate cells.  Inhibition of Twist1 is associated with 
downregulation of alpha-SMA, Col1a1 and CTGF, and reduces activation and 
migration of stellate cells and expression of the miR-214/199 family.  Inhibiting miR-
214-5p is associated with increased alpha-SMA, Col1a1 and stellate cell migration.  
Taken together, these findings suggest a novel negative feedback loop that regulates 
accumulation of fibrosis in the liver. 
In the next chapter, we report that miR-29a is downregulated significantly 
during liver fibrosis.  miR-29a targets many extracellular matrix proteins, including 
collagen, elastin and fibrillin.  Using an adeno-associated virus, we expressed miR-29a 
in hepatocytes of mice treated with carbon tetrachloride (CCl4).   We report a dramatic 
therapeutic benefit when maintaining miR-29a expression in hepatocytes.  Using an in 
vitro approach, we show that miR-29a is packaged into exosomes, and miR-29a is 
transferred from hepatocytes to stellate cells to regulate collagen expression.  Finally, 
we create an inducible miR-29a transgenic mouse, and future directions the lab will 
pursue to further characterize these therapeutically beneficial observations.   
This work establishes roles of two different miRNA families that are 
dysregulated during liver fibrosis.  Our efforts are great examples that point towards the 
need to consider miRNA expression on a cell-specific level.  Characterizing other 
miRNAs would lead to identification of specific biomarkers, novel mechanisms and 
individual therapeutic options in nearly every pathogenic setting.  
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1. CHAPTER 1. INTRODUCTION 
 
1.1 Liver fibrosis and public health 
Liver fibrosis is a reversible phenotype that is associated with increased 
deposition of extracellular matrix proteins, upregulation of proinflammatory cytokines, 
oxidative stress, apoptosis and steatosis (Lee et al., 2011).  Chronic viral infection, long-
term excessive alcohol intake, exposure to toxins and obesity contribute to the etiology of 
liver fibrosis, which, if left untreated, can develop into chronic liver disease and cirrhosis.  
According to the CDC, chronic liver disease and cirrhosis contributed to over 33,000 
deaths in the United States in 2011, making it one of the highest causes of preventable 
death (Hoyert et al., 2012).   
Liver fibrosis often presents as the primary phenotype which leads to functional 
complications, including coagulation disorders, bacterial infections and portal 
hypertension.  Because of the buildup of extracellular matrix proteins, liver architecture 
changes dramatically and hepatocyte function is compromised due to a disruption in cell-
to-cell contact or through altered blood flow.   
Chronic liver fibrosis is a progressive and long-developing disease.  As a result, 
success in clinical trials for liver fibrosis treatment has been limited.  Because no FDA-
approved pharmacotherapeutic options currently are available, the standard of care for 
someone with end-stage liver disease as a result of progressive liver fibrosis is an organ 
transplant.  However, considering the high cost to this procedure, the scarcity of donor 
grafts and increasing number of patients waiting for an organ (Figure 1-1A), this 




five years (Figure 1-1B).  Identifying the molecular mechanisms behind the progression 
of this disease would ameliorate these staggering numbers.  
Several genetic diseases present with a fibrotic phenotype.  Among them, the 
most prevalently diagnosed pediatric disorders and syndromes are congenital hepatic 
fibrosis, Wilson disease and alpha-1 antitrypsin deficiency (Taddei et al., 2008).   Each 
inherited disorder is associated with different primary defects.  In congenital hepatic 
fibrosis, bile ducts and blood vessels constrict and disallow bile, nutrients and other 
metabolites to be processed by the liver (Rawat et al., 2013).  Copper transport is 
compromised in patients with Wilson disease, causing an accumulation of copper in the 
liver that contributes to fibrosis development (Roberts et al., 2008).  Patients with alpha-1 
antitrypsin deficiency present usually during the third to sixth decade of life due to a 
mutation that leads to a buildup of neutrophil elastase, which in excess will attack and 
injure normal liver cells (Topic et al., 2012).  Although each presents with different initial 
symptoms, liver fibrosis develops in all three diseases.  
Because fibrosis of the liver undergoes periods of accumulation and regression 
over many year, many times it occurs asymptomatically, especially in patients with 
nonalcoholic fatty liver disease (Milic et al., 2012).  However, through meta-analysis and 
retrospective studies, it is becoming increasingly appreciated that liver fibrosis is a pre-
cancerous stage.  About 80% of patients who are diagnosed with hepatocellular 
carcinoma (HCC) present with liver cirrhosis (Llovet et al., 2003).  Recent data suggest 
that the mortality rate from HCC is increasing in developed countries (Deuffic et al., 
1998; El-Serag et al., 1999; La Vecchia et al., 2000).   Identifying molecular markers and 




drug therapies, and such approaches have been successful (Prickett et al., 2012; Peng et 
al. 2012; Lorenzen et al., 2011).  
 
1.2 The liver undergoes many cellular changes during fibrosis 
During liver fibrosis, tissue morphology dramatically changes.  Treatment of a 
hepatotoxin like carbon tetrachloride (CCl4) or ingestion of alcohol, both of which have 
been utilized in animal models in work described in this thesis, causes cell apoptosis, 
release of reactive oxygen species and paracrine stimulation of endothelial and hepatic 
stellate cells (HSC) (Lee et al., 2011).  Quiescent HSCs lose Vitamin A lipid droplets and 
transform into activated myofibroblasts that produce extracellular matrix proteins.  As the 
injury worsens, the organ scars, and disrupts cell-cell interactions, angiogenesis and 
blood flow (Jiao et al., 2009). 
Emerging mechanisms underlying stellate cell activation are being identified.  
While “classic” pathways like the PDGF and TGF-beta signaling pathways play a role 
both in activation of stellate cells and maintenance of activation, members in other 
pathways including the VEGF, NFkB and JAK/STAT signaling pathways have been 
implicated in regulation of HSC activation (Lee et al., 2011). 
Interestingly, liver fibrosis is a reversible phenotype.  Removal of the insult (i.e. 
CCl4 or alcohol) often leads to regression of fibrosis.  Lineage tracing studies have 
suggested that after removal of the insult, about half of myofibroblasts apoptose while the 
other half revert to an inactive phenotype that is similar to quiescent HSCs (Kisseleva et 
al., 2012).  Therapeutic approaches have focused on inactivating ECM-producing 




cytokines have had varying success to alleviate deposition of extracellular matrix proteins 
and activation of stellate cells.  Losartan, for example, has been limited as a therapeutic 
agent because it has both anti-fibrotic and anti-angiogenic effects (Parlakgumus et al., 
2013).  These nonspecific and unwanted effects call for a need to identify and develop 
more specific therapeutic options.    
 
1.3 miRNAs biogenesis, processing and function 
miRNAs have a unique processing mechanism that results in a 19-24 nucleotide 
molecule that negatively regulates translation.  After transcription, usually by RNA 
Polymerase II, the long pri-miRNA sequence is cleaved at the base of the primary stem 
loop by Drosha RNase III endonuclease (Lee et al, 2003).  The pre-miRNA hairpin is 
actively transported from the nucleus to the cytoplasm by Ran-GTP and the export 
receptor Exportin-5 (Yi et al., 2003; Lund et al., 2004).  Dicer, another endonuclease, 
processes the hairpin in the cytoplasm, and one mature miRNA strand is incorporated 
into the RNA-induced silencing complex (RISC), where it regulates protein and mRNA 
expression (Bartel, 2004). 
Understanding miRNA processing from Drosha through RISC has evolved over 
the past 15 years.  Originally, evidence based on thermodynamic free energy of the 
miRNA 3’ overhanging sequences suggested that one strand is preferentially processed 
while the other strand is degraded.  Recent studies indicate that both strands of a 
microRNA hairpin can be processed (Kuchenbauer et al, 2011), and the second strand, 
sometimes called the miRNA* (star) strand, may even have regulatory roles (Yang et al, 




strand bias which allows a cell to transcribe one primary transcript that produces two 
regulatory genes with different sets of targets.  
The human genome has over 1000 miRNAs, and each can regulate multiple 
genes, pathways and networks during normal and pathogenic physiology (Grimson et al., 
2007; Lewis et al., 2005).  miRNA dysregulation has been implicated as a factor 
associated with liver fibrosis (Roderburg et al., 2012; Li et al., 2012; Kwiecinski et al., 
2012; Kogure et al., 2012).  miRNAs have been overexpressed or repressed to understand 
their role in organ fibrosis (Lakner et al., 2012; Ogawa et al., 2012).  Understanding the 
different molecular networks where a specific miRNA functions will be vital to 
understand its importance in the development of therapies.  Studies described in Chapters 
2 and 3 assess expression and determine function of miR-214 and miR-29a during liver 
fibrosis. 
 
1.4 Therapeutic methods of gene delivery  
Understanding genetic changes during a pathogenic state has led to the 
development of strategies to regulate expression using viral vectors, mimics or inhibitors.  
Gene therapy that regulates miRNA expression has had success recently in small animal 
models (van Rooij et al., 2008), including therapy that targets the liver (Kota et al., 2009; 
Jopling et al., 2005).  The liver is an attractive organ for systemic therapeutic delivery of 
genetic material because it constantly encounters and interacts with circulating blood.  
Others have achieved cell-specific expression of viruses and nanoparticles, including 




Off-target effects present an issue when considering mode of delivery, and this 
becomes an important obstacle during preclinical and clinical testing.  Adeno-associated 
viruses are non-integrating viruses that have organ- and cell-specific tropism (Zincarelli 
et al, 2008).  Importantly, AAVs have been reported to have very little off-target effects, 
making them extremely enticing options for gene delivery.  An AAV product for 
treatment of lipoprotein lipase deficiency has even been licensed in Europe (Pollack, 
2012).   
In Chapter 3, we utilize AAV serotype 8 to deliver miR-29a to hepatocytes.   
Mice treated with one systemic injection of AAV8 develop no clinical signs of toxicity.   
Therapeutically, we report that delivery of miR-29a AAV is strongly associated with 
protection from and, in one model, regression of liver fibrosis.  This study serves as 
another example of successful systemic therapeutic delivery of genetic material to a 




1.5 Figures: Chapter 1  
Figure 1-1. UNOS data for solid organ transplants. 
 
A) UNOS data as of September, 2013.  B) Liver graft survival data for 1, 3 and 5 years 





2. CHAPTER 2. IDENTIFICATION OF A NOVEL NEGATIVE FEEDBACK 
LOOP INVOLVING MIR-214 AND TWIST1 IN LIVER FIBROSIS 
 
2.1 Introduction 
A growing number of publications have identified changes in microRNA 
(miRNA) expression that are associated with organ fibrosis.  Recognizing dysregulation 
of miRNA and identifying miRNA targets can lead to understanding of molecular 
mechanisms in a pathogenic setting.  We set out to examine miRNA dynamics during 
liver fibrosis using a published alcohol intake model (Lieber et al., 1982).  We 
comprehensively surveyed expression of over 350 miRNAs in whole liver tissue during 
fibrosis.  Our goal was to identify changes in whole tissue, determine cell-specific 
expression, and understand function of miRNAs during fibrosis.  We hypothesized that 
this approach would lead to discovery of novel molecular markers and mechanisms and 
could even lead to development of individual treatment options for patients with organ 
fibrosis. 
miRNAs have been reported to be co-expressed and function as genomic miRNA 
networks (Zhang et al., 2009; Guo et al., 2012; Mendell, 2008).  One group, the miR-
214/199 family, is transcribed from three different loci in the human genome, and some 
members of this group have been implicated in organ fibrosis (Murakami et al., 2011; 
Iizuka et al., 2012; Aurora et al., 2012).  However, cell specific expression and function 
of this miRNA family during liver fibrosis are unknown.  In this study, we identified that 
all unique sequences of the miR-214/199 family are upregulated in rodent liver fibrosis, 




nonparenchymal cells.  One member of the miR-214/199 family, miR-214-5p, 
specifically targets and negatively regulates its own transcription factor, Twist1, in 
stellate cells.  Interestingly, miR-214-5p is sufficient to regulate hepatic stellate cell 
activation, migration and collagen production.   
miR-214 and miR-199a are upregulated by Twist1, a mesenchymal cell 
transcription factor (Lee et al., 2009).  Both gain of Twist1 and loss of members of the 
miR-214/199 family have been associated with increases in cancer metastasis (Yang et 
al., 2006; Li et al., 2012).  During fibrosis, stellate cells lose lipid droplets, become 
activated and migrate to the site of hepatocellular injury.  We investigated the role of 
Twist1 and miR-214 in a fibrotic setting.  Interestingly, a knockout model of the entire 
hairpin of miR-214 is associated with increased cardiac fibrosis and decreased survival 
rate after induced myocardial infarction (Aurora et al., 2012), suggesting that miR-214 
could have a protective role during fibrosis.   
Here, we report that Twist1 is an important transcription factor that regulates 
expression of pro-fibrotic gene expression.  Inhibition of Twist1 is associated with loss of 
expression of a cohort of pro-fibrotic genes.  miR-214-5p directly targets and negatively 
regulates Twist1 in activated hepatic stellate cells, and loss of miR-214-5p upregulates 
Twist1 and downstream targets, including alpha-SMA and Col1a1.  Taken together, these 
findings imply mir-214-5p and Twist1 as members of an important negative feedback 
loop contributing to the control of stellate cell activation, migration and collagen 






2.2.1 miR-214-3p and miR-199a-3p are upregulated in human and rodent liver 
fibrosis. 
During liver fibrosis, activated stellate cells and collagen production increase.  
We treated male Lewis rats with a published model of alcohol intake to induce liver 
fibrosis (Lieber et al., 1982).  After six weeks of alcohol consumption, only the group 
treated both with alcohol and carbon tetrachloride (CCl4) (which we termed the 
‘combination group’) develop histological evidence of fibrosis (Figure 2-1A).  An 
increase in fibrosis is associated with an increase in alpha-smooth muscle actin-positive 
activated stellate cells in this cohort (Figure 2-1B).   
Dysregulation of miRNAs has been implicated in liver fibrosis (He et al., 2012; 
Vettori et al., 2012; Hinz et al., 2012; Haybaeck et al., 2011), and others have reported 
that miRNAs dynamically change in alcohol-related liver fibrosis (Bala et al., 2012).  We 
examined miRNA changes in all four groups, and compared those changes to our 
histological data.  In a miRNA qPCR array that detects expression of over 350 miRNAs, 
miR-214-3p and miR-199a-3p are two of most upregulated miRNAs in the combination 
group (Table 2-1).  Because different models of liver fibrosis have many commonalities 
both in histology and gene array expression, we cross-referenced our data from the 
alcohol-induced rat fibrosis model with a second rodent fibrosis model (described in 
Chapter 3).  Both miR-214-3p and miR-199a-3p are among 18 miRNAs that are 
upregulated by more than 1.5-fold in the fibrotic groups of both models, suggesting that 




Both miR-214-3p and miR-199a-3p are processed from DMN3os, a 6kb 
untranslated RNA that is transcribed from the opposite strand of an intron of DNM3 
(Loebel et al., 2005; Watanabe et al., 2008).  While DNM3os-specific miRNAs were 
upregulated, we do not detect a significant increase in DNM3 mRNA or protein in our 
model (unpublished data).  Furthermore, while Twist1 has been reported to upregulate 
DNM3os (Lee et al, 2009), there is no Twist1 consensus binding-site 5’ to the 
transcription start site of DNM3, implying that transcriptional upregulation of miR-214-
5p and miR199a-3p is independent of DNM3 transcription. 
To examine whether this group of miRNAs is upregulated during human liver 
fibrosis, we obtained samples that were scored by a pathologist as having portal fibrosis, 
bridging fibrosis or cirrhosis.  miR-214-3p and miR-199a-3p are significantly 
upregulated in the bridging and cirrhotic groups, and miR-214-3p is also significantly 
upregulated in patients with portal fibrosis (Figure 2-2A).  Interestingly, upregulation of 
miR-214-3p and miR-199a-3p has no significant correlation with hepatitis C infection 
(HCV), reported drug or alcohol use, or liver enzymes (Table 2-2), suggesting that 
upregulation of miR-214-3p and miR-199a-3p could be fibrosis-specific.  
We also observe upregulation of miR-214-3p and miR-199a-3p from serial 
biopsies of an individual patient who developed recurrent HCV after a liver transplant 
(Figure 2-2B).  miR-214-3p and mir-199a-3p expression in whole tissue steadily 
increases over a 15-month period as HCV recurred and fibrosis developed (Table 2-3). 
 
2.2.2 Both strands of miR-214 are equally expressed, and all unique strands of the 




The miR-214/199 family has four different miRNAs expressed from three 
conserved loci (Figure 2-4A).  The miR-214/199 family is transcribed from the opposite 
strand of introns of a family of genes called dynamins.  This miRNA family has 5 unique 
miRNA strands.  Recent studies indicate that both strands of a microRNA hairpin can be 
processed (Kuchenbauer et al., 2011), and the miRNA* (star) strand may even have 
regulatory roles (Yang et al., 2011).  miRBase reports deep sequencing reads of each 
strand for many miRNAs, and deep sequencing reads can imply strand bias during 
processing.  An in silico analysis of strand expression indicates that in about 11% of all 
miRNAs both strands are expressed in <1:2 ratio (3p:5p), suggesting that the miRNA* 
strand of these miRNAs may have a functional role.  Included in this group is mir-214, 
whose strands are expressed in nearly equal levels (Figure 2-3A).  Conversely, miR-199a 
had a biased ratio (>10:1).  The ratios of miR-214 and miR-199a were confirmed in our 
model, as mir-214 has a nearly 1:1 ratio in each group in our rat liver fibrosis model 
(Figure 2-3B). 
Given the evolutionary conservation of this miRNA family, we hypothesized that 
other unique strands in this family are upregulated.  Indeed, miR-214-5p, miR-199a-5p 
and miR-199b are also significantly upregulated in the combination group of our rodent 
fibrosis model.  Not only is DNM3 expression not significantly dysregulated during liver 
fibrosis, DNM1 and DNM2 message is unchanged (unpublished data).  We also 
measured miRNA expression for all five unique strands in this family in a second rodent 
model of liver fibrosis (described in Chapter 3).  All five strands after 8 weeks of CCl4 
treatment in BL/6 mice are significantly upregulated (Figure 2-4C), suggesting that the 





2.2.3 miR-214-5p has two mature transcripts. 
Although we report that mmu-miR-214-5p is significantly upregulated in rat liver 
fibrosis, miRBase reports that miR-214 has a different 5p mature sequence (Figure 2-5A).  
Since rno-miR-214-5p has a limited number of reported deep sequencing reads, we 
examined expression of rno-miR-214-5p in our rodent models.  Rno-miR-214-5p is 
significantly upregulated in both of our rodent models, including our mouse model, after 
induction of liver fibrosis (Figure 2-5B-C).  We tested rno-miR-214-5p expression from 
human miR-214 by transfecting an adeno-associated viral vector containing the entire 
hairpin of human miR-214 into HeLa cells.  Surprisingly, all three mature sequences of 
miR-214, including rno-miR-214-5p, are significantly upregulated after transfection with 
human miR-214 (Figure 2-5D), implying that at least three mature sequences are 
processed in human, mouse and rat miR-214. 
 
2.2.4 miR-214 is expressed predominantly in non-parenchymal cells, including 
activated stellate cells, during liver fibrosis. 
The liver is a heterogeneous organ consisting of many different cell types 
including hepatocytes, stellate cells, Kuppfer cells and endothelial cells.  Expression 
profiles in different cell types have revealed that miRNAs have tissue- and cell-specific 
expression (Santoro et al., 2013; Sood et al., 2006), and others have even developed 
methods to predict cell-specific miRNA expression (Lee et al., 2012).  We set out to 
examine the mir-214/199 family expression pattern during liver fibrosis in different cell 




liver (Figure 2-6), and an increase in expression in nonparenchymal cells correlates with 
an increase deposition of extracellular matrix proteins.  Additionally, this expression 
patterns overlaps a similar pattern of alpha-smooth muscle actin ( -SMA) expression 
(Figure 2-1B), suggesting that this family of miRNAs may be expressed in hepatic 
stellate cells.  An in silico analysis of cell specific expression of miR-214-3p and miR-
199a-5p indicates that, while both are expressed in the liver, uninjured hepatocytes do not 
express these miRNAs (Halushka, unpublished data).  Instead, this family of miRNAs is 
expressed more highly in adipocytes, fibroblasts and smooth muscle cells, indicating that 
these miRNAs may be exclusive to stellate cells and other collagen-producing cells.  
To determine cell-specific expression of the miR-214/199 family, we examined 
baseline expression in an activated stellate cell line (LX-2 cells), and compared it to three 
different hepatoctyte-derived lines, HuH7, HepG2 and primary human hepatocytes.  LX-
2 cells have increased expression of the miR-214/199 family compared to hepatocytes, 
pinpointing its expression to activated stellate cells (Figure 2-7A).   
During fibrosis, the total number alpha-SMA-positive activated stellate cells is 
increased.  Although the miR-214/199 family is upregulated in liver fibrosis, we cannot 
definitively rule out that the increase in the miR-214/199 family is merely the result of an 
increase in total stellate cell number.  To examine if processing of the miR-214/199 
family is increased in stellate cell, we treated LX-2 cells with a proinflammatory 
cytokine, TGF-beta.  TGF-beta treatment is associated with a significant upregulation of 
alpha-SMA, Col1a1, CTGF, FN1 and PDGF-R-beta (Figure 2-7B), all reported to 
increase during liver fibrosis (Chakraborty et al., 2012).  Twist1, miR-214-3p, miR-214-




there is an upregulation of Twist1 and the miR-214/199 family transcription or miRNA 
processing in stellate cells during fibrosis. 
 
2.2.5 miR-214-5p targets Twist1, which is upregulated in liver fibrosis. 
A consensus Twist1 binding-site has been reported upstream of DNM3os (Lee et 
al., 2009).  This sequence (CATATGT) is 5’ to the transcriptional start sites of miR-
199a-1 and miR-199b, suggesting that Twist1 may transcriptionally upregulate the entire 
miR-214/199 family.  Interestingly, the 3’ UTR of Twist1 has a conserved miR-214-5p 
binding site.  To test whether miR-214 interacts with its own transcription factor to 
regulate expression, we cloned the 3’ UTR of Twist1 into a luciferase vector and co-
transfected this vector with plasmids containing no miRNA, miR-214 or miR-199a into 
HeLa cells.  While luciferase activity does not change in cells co-transfected with miR-
199a, coexpression of miR-214 with the 3’UTR of Twist1 reduces luciferase expression 
by more than half (Figure 2-8A-B), indicating that miR-214 regulates expression of 
Twist1 protein expression.   
Next, we were interested to determine Twist1 expression in liver fibrosis.  Twist1 
mRNA and protein are significantly upregulated in the combination group (Figure 2-9A-
C).  Consistent with upregulation of Twist1, Twist2, a conserved homolog of Twist1, is 
increased after 4 weeks of CCl4 treatment (Figure 2-9D). 
 





Twist1 is a mesenchymal transcription factor that promotes growth, proliferation 
and cell migration (Qin et al., 2011).  miR-214 has been implicated as a factor controlling 
cancer cell migration (Li et al., 2012).  In addition, other have shown that knockout of 
miR-214 is associated with increased fibrosis and decreased survival rate in animals after 
induced myocardial infarction (Aurora et al., 2012).  Given that both Twist1 and the miR-
214/199 family are upregulated during liver fibrosis, we hypothesized that miR-214-5p 
could negatively regulate enhanced expression of Twist1 in stellate cells, limiting 
activation and migration.  We inhibited Twist1 expression and examined differential 
transcription of downstream targets, including pro-fibrotic genes.  Inhibition of Twist1 in 
LX-2 cells leads to significant downregulation of all five miR-214/199 members (Figure 
2-10B).  Twist-1 inhibition is also associated with a significant decrease in expression of 
alpha-SMA, CTGF, FN1 and MMP2 (Figure 2-10A), suggesting that Twist1 is necessary 
for expression of pro-fibrotic genes in activated stellate cells.  Phenotypically, cells 
treated with Twist1 siRNA have limited migration (Figure 2-10C-D), implying that 
Twist1 plays an important role in activation and migration of hepatic stellate cells. 
 
2.2.7 Inhibition of miR-214-5p is associated with increased activation, collagen 
production and migration of hepatic stellate cells. 
LX-2 cells are transformed hepatic stellate cells that express miR-214-3p and 
miR-214-5p equally.  Since miR-214-5p targets Twist1, which is sufficient to regulate 
expression of alpha-SMA, CTGF and FN1, we hypothesized that expression of miR-214-
5p could contribute to fibrosis progression in stellate cells.  Consistent with inhibition of 




Col1a1 (Figure 2-11).  Interestingly, Twist1 message and protein are also significantly 
increased (Figure 2-12A-C). 
Given the increase in Twist1 after inhibition of miR-214-5p, we were interested to 
examine the dynamics of reported downstream markers of Twist1.  miR-214-3p and miR-
199a-3p are significantly upregulated after inhibition of miR-214-5p.  However, after 
miR-214-3p inhibition, expression of Twist1 and other DNM3os miRNAs remain 
unchanged (Figure 2-12C).   
Since Twist1 is a mesenchymal-specific transcription factor, we examined 
expression of epithelial and mesenchymal markers after miR-214-5p inhibition.  While 
there is a non-significant decrease in E-cadherin, an epithelial marker (unpublished data), 
Vimentin, Zeb1 and Zeb2 are significantly increased after inhibition of only miR-214-5p 
in LX-2 cells (Figure 2-12D).  However, there was no significant upregulation of 
mesenchymal markers in cells treated with miR-214-3p.   
To determine the functional effect of inhibiting miR-214-5p in LX-2 cells, we 
performed a scratch assay to evaluate cell migration (Liang et al., 2007).  After 18 hours, 
cells transfected with miR-214-5p, but not miR-214-3p, migrate significantly further 
compared to those transfected with scrambled inhibitor (Figure 2-13A-B).  A similar 
migration pattern is observed in cells overexpressed with Twist1, suggesting that miR-
214-5p may control cell migration in a Twist1 dependent manner. 
 
2.2.8 Inhibition of miR-214-5p exacerbates activation, migration and collagen 




We have shown that regulating expression of Twist1 and miR-214-5p have nearly 
opposite effects – inhibiting Twist1 limits expression of pro-fibrotic genes and the miR-
214/199 family while inhibiting miR-214-5p is associated with an increase in pro-fibrotic 
gene and other members of the miR-214/199 family.  We hypothesized that miR-214-5p 
is regulating Twist1 expression in LX-2 cells.  To test this, we cloned Twist1 (including 
its 3’UTR) into pcDNA3+. Transfecting this vector while inhibiting miR-214-5p causes a 
significant increase in Twist1 (Figure 2-14A-B).  We also report a significant 
transcriptional upregulation of miR-214-3p, miR-199a-3p and miR-199b, as well as pro-
fibrotic markers alpha-SMA, Col1a1, CTGF and PDGF-R-beta (Figure 2-14C-D). 
Phenotypically, overexpression of Twist1 leads to migration of LX-2 cells.  
Interestingly, overexpressing Twist-1 while inhibiting miR-214-5p causes LX-2 cells to 
migrate significantly more quickly compared with overexpression of Twist1 transfected 
with scrambled inhibitor (Figure 2-15A-B), indicating that miR-214-5p and Twist1 are 
important in activation and migration of stellate cells.   
 
2.3 Discussion 
In this study, we examined expression of the miR-214/199 family, a group of 
miRNAs that are under transcriptional control of Twist1.  We determined that 
upregulation of the miR-214/199 family was associated with an increase in human and 
rodent liver fibrosis.  For the first time, we have shown that upregulation of miR-214-3p 
and miR-199a-3p can be followed in an individual patient during progression of fibrosis 
after organ transplant.  Increased expression of miR-214-3p and miR-199a-3p even 




These results indicate that the miR-214/199 family is a reliable biomarker of varying 
degrees of liver fibrosis both in a cohort of patients and even in an individual patient. 
Though we examined homogenous whole liver tissue, it is important to 
understand miRNA expression in a cell-specific manner.  Ascertaining cell-specific 
expression of a miRNA family would help identify mRNA targets and functional 
consequences of dynamic change during injury.  As indicated by in situ hybridization, 
miR-214 is expressed predominately in non-parenchymal cells, including hepatic stellate 
cells, endothelial cells and Kuppfer cells, during liver fibrosis.  Our in vitro data 
determined that expression of the miR-214/199 family was concentrated in stellate cells, 
and expression of miRNAs in this family was increased after TGF-beta-induced 
activation of stellate cells, suggesting that upregulation of the miR-214/199 family in 
whole tissue is due not only to an increase in myofibroblasts but also to an increase in 
individual cell expression of this family.  Consistent with these observations, recent 
studies have reported that members of this family are upregulated in cells transitioning to 
a mesenchymal state in the other organs (Denby et al., 2011).   
Original experimental evidence indicated that miRNAs preferentially express one 
strand and degrade the other strand.  Using miR-214, we have demonstrated that both 
strands of a miRNA are equally expressed in the liver, which opens up the possibility of 
two different sets of miRNA targets.  Here, miR-214-5p (the star strand) regulates Twist1 
expression during stellate cell activation.  According to miRBase data, equal expression 
of both strands represents 11% of all miRNA biology, which increases the total number 




After cleaving by Drosha, the average pri-miRNA hairpin length is 60 nucleotides 
(Starega-Roslin et al., 2011).  However, the hairpin of miR-214 is 115 nucleotides, nearly 
twice the average size.  miRBase reports that rno-miR-214-5p has a different mature 
sequence, which is proximal to the base of the hairpin.  Although rno-miR-214-5p differs 
from the mouse and human sequence, all three species have identical rat- and 
human/mouse-specific mature miR-214-5p nucleotide sequences.  To our surprise, all 
three mature miRNAs are significantly upregulated in humans, mice and rats.  There is a 
one-nucleotide overlap between rno-miR-214-5p and mmu/hsa-miR-214-5p, implying 
that both mature sequences cannot be processed from the same hairpin.  However, our 
observations indicate that miR-214 can process at least three mature sequences.  Because 
of this, miR-214 might have three unique sets of targets.  It would be interesting to 
understand if increased miRNA hairpin size correlates to more than two predicted mature 
miRNAs.  Further studies to explore rno-miR-214 targets would elucidate this novel and 
unique phenomenon in miRNA biology, and indicate if this observation has a functional 
consequence.   
Proliferating hepatic stellate cells are important producers of extracellular matrix 
proteins during liver injury.  They migrate to the site of injury, producing ECM proteins 
to protect damaged hepatocytes.  Recent studies on individual members of the miR-
214/199 family have suggested that this family may act as negative regulators of 
proliferation (Zhang et al., 2012; Jia et al., 2012; Derfoul et al., 2011).  Using data from 
these experiments, we propose a model of miR-214-5p’s role in liver fibrosis (Figure 2-
16).  During alcohol-induced liver fibrosis, Twist1 mRNA and protein are upregulated.  




binding site, suggesting transcriptional regulation.  miR-214 interacts with a conserved 
7merM8-binding site in the 3’UTR of Twist1.  When inhibiting expression of miR-214-
5p, Twist1, mRNA of pro-fibrotic genes and mesenchymal transcription factors are 
significantly upregulated.  miR-214-5p expression in LX-2 may regulates hepatic stellate 
cell activation, collagen production and mesenchymal gene expression through Twist1.  
Others have shown that miR-214 increases upon activation of primary hepatic 
stellate cells (Maubach et al., 2011).  However, the role of miR-214 in activated stellate 
cells was unknown.  For the first time, we have provided functional evidence that this 
interaction controls a stellate cell phenotype.  Overexpressing Twist1 in LX-2 cells leads 
to faster cell migration over 18 hours.  In the same manner, inhibiting miR-214-5p in the 
same cell type not only upregulates pro-fibrotic and mesenchymal markers but also leads 
to a faster cell migration.   Finally, we confirmed the functional interaction between 
Twist1 and miR-214-5p when we overexpressed Twist1 (including its 3’UTR) while 
inhibiting miR-214-5p.  This cohort has increased expression of Twist1, the miR-214/199 
family and pro-fibrotic markers.  Taken together, our data suggest that miR-214-5p 
regulates activation and migration of stellate cells through Twist1. 
Liver fibrosis and cirrhosis is the strongest predisposing factor of hepatocellular 
cancer.  80% of patients with hepatocellular carcinoma are reported to have cirrhotic 
livers (Llovet et al., 2003).   Loss of expression of members in the miR-214/199a family 
has been associated with increased metastasis (Li et al., 2012), and others have shown 
that pharmaceutically inhibiting Twist1 inhibits migration of breast cancer cells (Pai et 




5p plays a prominent role in limiting stellate cell migration.  By targeting Twist1, miR-
214-5p might be suppressing initiation of tumor differentiation in the liver.   
 This study has, for the first time, identified a negative feedback loop involving 
Twist1 and miR-214-5p that contributes to activated hepatic stellate cells.  Twist1 has not 
been studied as a regulator of liver fibrosis in this detail.  Here, we show that it is 
sufficient to control expression of alpha-SMA and Col1a1, and induce migration of 
activated stellate cells.  Importantly, expression of miR-214-5p limits increased 
expression of Twist1 and its downstream targets.  These studies point out a unique 
paradox in miRNA biology: an increase in miR-214 during liver fibrosis may in fact be 
protective against cirrhosis by negatively regulating Twist1, a gene product that is also 
upregulated.  One would predict that treating non-parenchymal liver cells in vivo with 
mimics or an overexpression vector would ameliorate liver fibrosis.  Alternately, 
studying a genetic model knocking out miR-214 under fibrotic conditions would further 
elucidate miR-214’s role during liver disease.  
 
2.4 Materials and methods 
2.4.1 Animal Models. 
Animals were housed and experiments were performed with approval by the 
Johns Hopkins School of Medicine Animal Care and Use Committee.  Seven- and eight-
week old male Lewis rats were divided into four groups and received the following: an 
isocaloric control diet according to the Lieber–DeCarli Regimen (Lieber et al., 1982); a 
diet with 7% ethanol; an isocaloric diet with biweekly injections of 0.1 mL/kg carbon 




and CCl4.  Two- and three-month-old C57BL/6 female mice were given 1 mL/kg of CCl4 
intraperitoneally biweekly for zero, one, four or eight weeks.  CCl4 was diluted in corn 
oil.  mT/mG mice (stock number 007576, The Jackson Laboratory (Jax), Bar Harbor, 
ME) were crossed to Twist2:cre (008712, Jax).  The resulting offspring was treated with 
1ml/kg CCl4 for zero or four weeks. At the conclusion of the experiments, animal livers 
were perfused with cold PBS and harvested. 
 
2.4.2 Human Samples. 
RNA from 10-50 m formalin-fixed, paraffin-embedded sections of livers with 
varying degrees of fibrosis was isolated using Trizol (Invitrogen, Carlsbad, CA), 
according to the manufacturer’s protocol.  Samples were used in accordance with the 
Johns Hopkins School of Medicine Institutional Review Board. 
 
2.4.3 Histology. 
Whole liver tissue was fixed in 10% formalin (Sigma-Aldrich) overnight.  The 
tissues then were transferred to 70% ethanol and embedded in paraffin.  5µm sections of 
tissue were cut and stained with Masson’s trichrome by the Johns Hopkins Reference 
Histology Lab (Baltimore, MD).    
 
2.4.4 MicroRNA Array. 
Total rat liver RNA was extracted using a mirVana miRNA Isolation Kit 
(Ambion, Inc, Austin, TX) according to the manufacturer’s protocol.  RNA was DNase 




transcribed without pre-amplification using Megaplex RT Primers (Rodent Pool A v2.0; 
Applied Biosystems, Carlsbad, CA) and TaqMan MicroRNA Reverse Transcription Kit 
(ABI), according to the manufacturer’s protocol.  The microarray was run on the 7900HT 
Fast Real-Time PCR System with TaqMan Array Rodent MicroRNA A Cards v2.0 
(ABI), according to the manufacturer’s protocol. The geometric mean of each plate was 
used for normalization. 
 
2.4.5 Immunostaining. 
Formalin-fixed, paraffin-embedded tissues were sectioned.  5 μm sections were 
transferred to Superfrost/Plus Microscope Slides (Fisher Scientific, Pittsburgh, PA) and 
melted onto the slide for 30’ at 60°C.  The tissues were stained using monoclonal anti-α-
smooth muscle actin conjugated to Cy3 (Sigma-Aldrich), diluted 1:100 in PBST.  Tissues 
were counterstained with Hoechst 33258 (Molecular Probes, Eugene, OR), mounted 
using Prolong Gold Antifade Reagent (Invitrogen, Carlsbad, CA), and subsequently 
imaged under identical conditions. 
 
2.4.6 In situ Hybridization. 
6 μm sections were cut in RNase free conditions, and incubated with double (5’ 
and 3’)-DIG labeled probe for miR-214 (Exiqon, Woburn, MA), according to the 
manufacturer’s protocol, and anti-DIG-AP (Roche, Branchburg, NJ) was used to detect 
miR-214.   
 




LX-2 cells (generously provided by James Potter and Anirban Maitra), 
immortalized human hepatic stellate cells, were grown in DMEM supplemented with 
10% fetal bovine serum (FBS), penicillin and streptomycin.  Cells were transfected in 
triplicate with miRIDIAN Hairpin Inhibitors (Thermo Fisher Scientific, Waltham, MA) 
or siRNA (Santa Cruz Biotechnology, Inc., Dallas, TX) using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol.  Media was changed 8-12 hours 
after transfection and RNA and protein lysates were isolated 24 hours after transfection 
as previously described.   
 
2.4.8 TGF-beta Treatment of LX-2 Cells. 
LX-2 cells were grown to 90% confluence.  They were washed, and normal 
growth media was changed with serum-starved media (DMEM supplemented with 0.2% 
fetal bovine serum (FBS), penicillin and streptomycin) for 24 hours, at which time a 
subset of cells was transfected with scrambled or Twist1 siRNA.  Cells then were treated 
with 5ng/ml TGF-beta (Roche) in serum-starved media.  RNA was isolated 24 hours 
later. 
 
2.4.9 RNA Isolation and qPCR. 
For animal and in vitro samples, total RNA was isolated from whole liver tissue 
using Trizol (Invitrogen) according to manufacturer’s protocol.  RNA was DNAse treated 
(Invitrogen), according to the manufacturer’s protocol, and was reverse transcribed using 
TaqMan MicroRNA Reverse Transcription Kit (ABI) with miRNA specific primers 




non-miRNAs, all according to the manufacturer’s protocol.  qPCR was performed using 
pre-designed TaqMan primers and probes (ABI), according to manufacturer’s protocol.  
qPCR using primers for alpha-SMA, Col1a1, CTGF, FN1, PDGF-R-b, TGF-beta, 
MMP9, MMP2, TIMP-1, Twist1, E-cadherin, N-cadherin, Vimentin, Zeb1, Zeb2, DNM1 
DNM2, and DMN3 was performed using Fast SYBR Green Master Mix (ABI).  Genes 
amplified using SYBR Green were normalized to beta-Actin.  The 2(-delta delta C(T)) 
Method was used to analyze PCR reactions. 
 
2.4.10 Protein Isolation and Western Blot. 
25 mg of homogenized tissue and LX-2 cells were suspended in RIPA buffer 
supplemented with Protein Inhibitor Cocktail (Sigma), according to manufacturer’s 
protocol.  Lysates were quantified using a BCA protein assay (Pierce, Rockford, IL).   
10-50 μg was loaded in each lane, and after transfer, the membrane was probed for 
Twist1 (Abcam, Cambridge, MA), DNM3 (Abcam) or b-Actin (Sigma).  Secondary 
antibodies (LI-COR, Lincoln, NE) were used to enhance detection of lysates, and signals 
were visualized using an Odyssey scanner (LI-COR).   
 
2.4.11 Molecular Cloning. 
Hsa-miR-214 and hsa-miR-199a were amplified and fragments were cloned into 
pAAV8 ef1a-eGFP at the FseI site and sequenced. The 3’UTR of Human Twist1 was 
cloned into the pGL3 vector at the XbaI site.  Human Twist1_3’UTR was cloned into the 
EcoRI site of the pcDNA3+ vector. Clones positive by restriction digest were sequenced. 





2.4.12 In silico Strand Bias Analysis. 
Deep sequencing reads from all miRNAs on TaqMan Array Rodent MicroRNA A 
Cards v2.0 (described above) were recorded from the miRBase website.  Read ratios 
were divided into three categories based on 3p:5p expression: < 1:2, 1:2 – 1:5, and > 1:5.   
To examine miR-214 and miR-199a strand bias in each rat cohort, each 5p strand was 
normalized to the 3p strand and all groups were normalized to miR-214 in the diet control 
group. 
 
2.4.13 Luciferase Reporter Assays. 
2.5×10
5
 HeLa cells were plated in triplicate wells of a 24-well plate and transfected 24 
hours later with 500 ng of a pAAV8 plasmid (Control, miR-214 or miR-199a), 100 ng of 
the indicated pGL3 3' UTR reporter construct and 5 ng of phRL-SV40 (Promega, 
Madison, WI) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol. 24 hours after transfection, cells were lysed and assayed for firefly and renilla 
luciferase activity using the Dual-Luciferase Reporter Assay System (Promega). Firefly 
luciferase activity was normalized to renilla luciferase activity for each transfected well.  
 
2.4.14 Cell Migration Assay. 
6-well cell culture plates were coated with poly-L-lysine (Sigma), and cells were 
plated and a scratch was made as previously described
 
[26].  Briefly, cells were 
transfected with gene plasmids (pcDNA3_Twist1_3’UTR), siRNA (Scrambled siRNA or 




214-3p; Thermo Scientific) using Lipofectamine 2000.  After 24 hours, a scratch was 
made with a p200 tip, and cells were washed with PBS and examined at 12 or 18 hours 
after the scratch.  At time = 0h, at least 10 images were taken, and at time = 12 hours or 
18 hours, at least 20 images were taken.  For each image, ImageJ was used to measure the 
area void of migrating cells.   
 
2.4.15 Statistics. 
A student two-tailed t-test was used to determine significance for all qPCR, 





2.5 Tables: Chapter 2 
Table 2-1. miRNAs upregulated by 1.5-fold in rodent models of liver fibrosis. 
Assay 








mmu-miR-214 1.00 21.03 1.00 1.88 
mmu-miR-434-3p 1.00 16.81 1.00 1.65 
mmu-miR-199a-3p 1.00 14.08 1.00 1.57 
mmu-miR-181c 1.00 14.04 1.00 2.78 
mmu-miR-409-3p 1.00 5.91 1.00 10.42 
mmu-miR-34a 1.00 5.58 1.00 3.11 
mmu-miR-301a 1.00 5.43 1.00 1.50 
rno-miR-351 1.00 5.12 1.00 1.77 
mmu-miR-15b 1.00 4.74 1.00 2.44 
mmu-miR-125a-5p 1.00 3.79 1.00 1.72 
mmu-miR-142-3p 1.00 3.40 1.00 1.76 
mmu-miR-99b 1.00 2.61 1.00 1.74 
mmu-miR-25 1.00 2.50 1.00 1.64 
mmu-miR-142-5p 1.00 2.11 1.00 1.94 
mmu-miR-34b-3p 1.00 2.03 1.00 2.35 
mmu-miR-342-3p 1.00 1.96 1.00 1.99 
mmu-miR-497 1.00 1.79 1.00 2.47 
mmu-miR-324-5p 1.00 1.58 1.00 1.69 
 
Rat model = 6 weeks of EtOH/CCl4 in male Lewis rats. 
Mouse Model = 8 weeks of biweekly CCl4 injections. 





 Table 2-2. Clinical observations of patients with liver fibrosis. 
 
*Self-reported 
HCV+: Hepatitis-C positive 
AST: Aspartate aminotransferase. 










2.6  Figures: Chapter 2 
Figure 2-1. Combination treatment of ethanol and CCl4 is associated with increases in 
fibrosis and activated stellate cells. 
 
A) Representative 10x images of 5 µm liver sections with Maisson trichrome stain.  B) 
Representative 10x images of 5 µm liver sections stained with alpha-SMA (red) and 














Figure 2-2. Upregulation of miR-214-3p and miR-199a-3p in human fibrosis.  
 
A) Expression of miR-214-3p and miR-199a-3p are significantly upregulated in patients 
with pathologist-scored fibrosis.  All groups were compared to group with no fibrosis.  B) 
Expression of miR-214-3p and miR-199a-3p in an individual liver transplant recipient as 
fibrosis and hepatitis C recurred.  All samples are relative to the two-month biopsy.  
Relative expression was normalized to 18s rRNA (* = p-value  < 0.05).  Error bars 




Figure 2-3. miR-214 has no post-transcriptional processing bias.  
 
A) miRBase deep sequencing reads comparing 3p reads against 5p reads.  miRNAs were 
classified as having 3p:5p read ratios of <1:2 (red), between 1:2 and 1:5 (black), and  
>1:5 (blue).  miR-214 and miR-199a are indicated by arrows.  B) 3p:5p read ratios of 




ratios were normalized to miR-214 3p:5p read ratio in the diet control group. Error bars 





Figure 2-4. All five unique mature sequences, transcribed from three loci, are 




A) The miR-214/199 family is transcribed from the opposite strand of three dynamin 
genes at three different loci in the human genome.   B) All five unique mature sequences 
are upregulated in the combination group of the rat alcohol-induced liver fibrosis model.  
C) All five unique mature sequences are upregulated after eight weeks of CCl4 treatment 
in BL/6 mice.  All groups were normalized to the Diet Control or No CCl4 groups, 
respectively.  All samples were normalized to 18s rRNA (* = p-value  < 0.05). Error bars 





Figure 2-5. Rno-miR-214-5p, a third mature strand of miR-214, is expressed in 




A) miRBase reports that hsa-miR-214-5p and mmu-miR-214-5p differ from rno-miR- 
214-5p (all in pink, top of hairpin).  Note: the mature miR-214-5p sequences do not differ   
for each mature sequence among species.  B-C) All three unique mature miR-214 
sequences are significantly upregulated in the rat alcohol-induced and mouse CCl4 
fibrosis model.  D) Transfection of the entire hairpin of miR-214 into HeLa cells using an 
AAV-vector leads to processing of all three miR-214 mature sequences.  Rat and mouse 
cohorts were normalized to the Diet Control or No CCl4 groups, respectively.  HeLa cells 
transfected with miR-214 were normalized to transfection with control pAAV.  All 
samples were normalized to 18s rRNA (* = p-value  < 0.05). Error bars represent one 




Figure 2-6. miR-214 is expressed predominantly in nonparenchyml cells. 
 
10x images of miR-214 expression (purple) in rat alcohol-induced liver fibrosis model.  






Figure 2-7. The miR-214/199 family is highly expressed in stellate cells and is 






A) Relative expression of all five unique sequences in the miR-214/199 family, relative 
to LX-2 cell expression.  B) Expression of pro-fibrotic genes in LX-2 cells after TGF-
beta treatment.  C) Expression of the miR-214/199 family in LX-2 cells after TGF-beta 
treatment. Pro-fibrotic genes were normalized to b-Actin, and the miR-214/199 family 
was normalized to 18s rRNA (* = p-value  < 0.05).  Error bars represent one standard 









Figure 2-8. Twist1 is a conserved target of miR-214. 
 
A) Twist1 has a conserved binding site for miR-214-5p  B) HeLa cells were co-
transfected with pGL3_Luc_Twist1-3’UTR and a AAV-vector with no miRNA, miR-214 
or miR-199a.  Expression of luciferase was normalized to renilla (* = p-value  < 0.05). 









A) Twist1 Western blot in rat alcohol-induced fibrosis model.  B) Quantification of 
Twist1 Western blot normalized to the diet control cohort.  Individual lanes normalized to 
beta-Actin C) Twist1 mRNA expression in rat fibrosis model. All samples are relative to 
the diet control cohort.  Relative expression was normalized to 18s rRNA D) 
Representative 10x images of Maisson trichrome-stained slides and epifluorescent 
membrane expression of mTomato (red) and eGFP (green) in Twist2:Cre/+; mTmG/+ 
mice after 4 weeks of CCl4 treatment.  Cells were counterstained with DAPI (blue). (* = 





Figure 2-10. Inhibition of Twist1 in LX-2 cells limits stellate cell activation, migration 





A) mRNA expression of pro-fibrotic genes in LX2 cells 24 hours after transfection of 
scrambled or Twist1 siRNA. All samples are relative to cells treated with scrambled 
siRNA.  Relative expression was normalized to beta-Actin.  B) Expression of the miR-
214/199 family in LX2 cells 24 hours after transfection of scrambled or Twist1 siRNA. 
All samples are relative to cells treated with scrambled siRNA.  Relative expression was 
normalized to 18s rRNA. C) 10x representative images of LX-2 cells treated with 
scrambled or Twist1 siRNA at t=0h and t=12h post-scratch.  D) Quantified cell migration 
12 hours after scratch.  ImageJ was used to measure area devoid of cell migration (* = p-




Figure 2-11. Inhibition of miR-214-5p in LX-2 cells is associated with increase in 
alpha-SMA and Col1a1. 
 
mRNA expression of alpha-SMA and Col1a1 in LX2 cells 24 hours after transfection 
with scrambled, miR-214-5p or mir-214-3p inhibitors. All samples are relative to cells 
treated with scrambled inhibitor.  Relative expression was normalized to beta-Actin (* = 










Figure 2-12. Inhibition of miR-214-5p in LX-2 cells causes upregulation of Twist1 and 





A) Twist1 Western blot in LX-2 cells transfected with miR-214 inhibitors.  B) 
Quantification of Twist1 Western blot normalized to the group treated with scrambled 
inhibitor.  Individual lanes normalized to beta-Actin. C) mRNA expression of Twist1 and 
the miR-214/199 family in LX2 cells 24 hours after transfection of scrambled, miR-214-
5p or mir-214-3p inhibitors. All samples are relative to cells treated with scrambled 
inhibitor.  miRNA Relative expression was normalized to 18s rRNA and Twist1 was 
normalized to beta-Actin.  D) mRNA expression of mesenchymal genes in LX2 cells 24 
hours after transfection of scrambled, miR-214-5p or mir-214-3p inhibitors. All samples 
are relative to cells treated with scrambled inhibitor.  Relative expression was normalized 






Figure 2-13. Inhibition of miR-214-5p is associated with an increase in stellate cell 
migration. 
 
A) 10x representative images of LX-2 cells treated with Twist1 or miR-214 inhibitors at 
t=0h and t=18h post-scratch.  B) Quantified cell migration 18 hours after scratch.  ImageJ 
was used to measure area devoid of cell migration (* = p-value  < 0.05).  Error bars 





Figure 2-14.  miR-214-5p targets Twist1 to limit expression of the miR-214/199 family 
and pro-fibrotic genes. 
 
A) Twist1 Western blot in LX-2 cells transfected with Twist1 and miR-214 inhibitors.  




and scrambled inhibitor.  Individual lanes normalized to beta-Actin. C) mRNA 
expression of the miR-214/199 family in LX2 cells 24 hours after transfection of Twist1 
and scrambled, miR-214-5p or mir-214-3p inhibitors. All samples are relative to cells 
treated with Twist1 and scrambled inhibitor.  Relative expression was normalized to 18s 
rRNA.  D) mRNA expression of pro-fibrotic genes in LX2 cells 24 hours after 
transfection of Twist1 and scrambled, miR-214-5p or mir-214-3p inhibitors. All samples 
are relative to cells treated with Twist1 and scrambled inhibitor.  Relative expression was 
normalized to beta-Actin (* = p-value  < 0.05).  Error bars represent one standard 







Figure 2-15. miR-214-5p targets Twist1 to limit stellate cell migration. 
 
 
A) 10x representative images of LX-2 cells treated with Twist1 and miR-214 inhibitors at 
t=0h and t=12h post-scratch.  B) Quantified cell migration 12 hours after scratch.  ImageJ 
was used to measure area devoid of cell migration (* = p-value  < 0.05).  Error bars 





Figure 2-16. Proposed model of negative feedback loop between miR-214-5p and 
Twist1 in hepatic stellate cells. 
 
Liver injury upregulates Twist1, which transcriptionally upregulates the miR-214/199 
family and Twist1 dependent mRNAs.  miR-214-5p limits additional activation of 







3. CHAPTER 3. HEPATIC MAINTENANCE OF MIR-29A PROVIDES NON-
CELL AUTONOMOUS PROTECTION DURING LIVER FIBROSIS  
3.1 Introduction 
Using an approach similar to the model described in Chapter 2, we induced liver 
fibrosis in a cohort of wild type rodents and investigated changes in miRNA expression.  
This chapter will describe miRNA changes during carbon tetrachloride-induced liver 
fibrosis in C57BL/6 wild type female mice.  Over an eight-week period, mice given 
biweekly injections of CCl4 developed progressive fibrosis.  Our goal was to identify 
miRNAs with differential patterns of expression, predict and test targets, and examine if 
expression could be manipulated to treat fibrosis. 
Some miRNAs are processed as families and have conserved targets in the same 
pathways or gene networks (Zhang et al., 2009; Guo et al., 2012; Mendell, 2008).  In our 
liver fibrosis model, the entire miR-29 family, which has three members transcribed from 
2 loci, is downregulated.  Downregulation of miR-29 has been implicated in organ 
fibrosis, including renal, lung and cardiac fibrosis (Wang et al., 2012; Cushing et al., 
2011; van Rooij et al., 2008).  During fibrosis, the organ undergoes homeostatic changes 
during which myofibroblasts produce extracellular matrix (ECM) proteins, including 
members of the collagen, elastin and fibrillin families.  ECM proteins replace normal 
parenchyma, inhibit vascular development and disrupt cell-to-cell contact, all of which 
lead to impaired liver function.  Many members of these ECM families have conserved 
predicted binding sites for miR-29a, suggesting that miR-29a may act as a negative 




Because miR-29 was downregulated in liver fibrosis, we postulated that 
modulation of miR-29a could ameliorate liver fibrosis and potentially restore normal 
liver histology and function. The liver possesses the ability to induce cell turnover and 
promote regression of fibrosis.  Targeting cells in the liver to overexpress miR-29a could 
help to create a normal physiologic environment by inhibiting initial fibrosis 
development and even advanced scarring. 
The liver metabolizes toxins and other foreign matter, making it a very appealing 
organ for foreign gene therapy delivery.  In fact, others have had success delivering genes 
to the liver (Sands, 2010; Wang et al., 2008; Hu et al., 2013).  Since systemic delivery of 
adeno-associate virus (AAV) serotype 8 predominantly infects hepatocytes, we 
administered miR-29a using a self-complementary AAV8 delivery system via a single 
tail vein injections and assessed collagen deposition in the organ after induced injury.   
In this chapter, we present results from the low-density array qPCR at different 
stages of progressive fibrosis.  We identify that miR-29a is downregulated, and we 
deliver miR-29a to the liver to restore expression.  Our goal was to inhibit fibrosis 
development using a negative regulator or extracellular matrix proteins.  Histologically, 
not only was fibrosis inhibited, it was reversed in a clinically relevant model.  We 
examine cell specific expression, and determine viral delivery primarily infects 
hepatocytes.  Finally, we investigate a non cell-autonomous mechanism based on 
identification of the virus in hepatocytes and collagen production in myofibroblasts, 
including stellate cells.  Taken together, these data suggest that hepatocellular expression 
of miR-29a is an important regulator of liver fibrosis by limiting collagen expression in a 





3.2.1 The miR-29 family is downregulated in carbon tetrachloride-induced hepatic 
fibrosis. 
To understand miRNA dynamics under liver fibrotic conditions, we utilized a 
published approach to induce liver fibrosis using carbon tetrachloride (CCl4).  2- and 3 
month old C57BL/6 wild type female mice were given biweekly injections of CCl4 for 0, 
1, 4 and 8 weeks, and mice developed progressive fibrosis over the 8-week period (Figure 
3-1A).  Using a low-density array qPCR, we assessed expression of over 350 miRNAs at 
each time point.  At 8 weeks of CCl4 treatment, three members of the miR-29 family 
were among the 60 most downregulated miRNAs (Table 3-1, highlighted in yellow).  
Using individual assays, we confirmed that all three members of the miR-29 family are 
significantly downregulated at 4 and 8 weeks (Figure 3-1B).  Interestingly, we did not 
detect a significant change in primary miR-29a, suggesting that downregulation of at 
least miR-29a could be due either to instability of the mature miRNA or decrease in 
miRNA processing.   
Since about 80% of the mass of a normal liver consists of hepatocytes, we 
reasoned that downregulation of miR-29 could be specific to hepatocytes.  To test this 
hypothesis, we treated primary human hepatocytes with a proinflammatory cytokine, 
TGF-beta.  After 24 hours, all three mature sequences of miR-29 were significantly 
downregulated while other hepatocyte-specific miRNAs expressed remained constant 
(Figure 3-1C).  Consistent with our in vivo observations, primary-miR-29a did not 
decrease, suggesting that downregulation of the miR-29 family in hepatocytes is due to 





3.2.2  Systemic injection of scAAV8.miR-29a.eGFP to hepatocytes is not toxic. 
Among the predicted targets of the miR-29 family are extracellular matrix 
proteins, including members of the collagen, elastin and fibronectin families (Lewis et al., 
2005).  We hypothesized that augmenting expression of miR-29a using a non-integrating 
virus could ameliorate fibrosis development.  We cloned the miR-29a hairpin 
downstream of a ubiquitous promoter, elongation factor 1 alpha (Figure 3-2A).  During 
post-transcriptional processing of this vector, miR-29a is cleaved and processed while 
enhanced green fluorescent protein (eGFP) is translated.   We transfected serial dilutions 
of the AAV vector into HEK-293 cells.  Both miR-29a and eGFP expression steadily 
increased as we steadily increased the amount of transfected vector (Figure 3-2B and 3-
2D).   
  We delivered 2x10
11
 AAV genomes to a cohort through one systemic tail vein 
injection (Figure 3-3A).   After 4 weeks, there was no evidence of toxicity, as seen by 
histological examination (Figure 3-3B), bilirubin and liver function tests (unpublished 
data).  eGFP was readily detectable in more than 50% of cells in the liver (Figure 3-3C).  
Surprisingly, there was no increase in primary or mature miR-29a (Figure 3-3D), 
suggesting either that the viral dosage was not sufficient to overexpress miR-29a, or that 
miR-29a expression in the liver is tightly regulated.   
We stained liver sections with eGFP and markers for hepatocytes or stellate cells 
(Figure 3-4).  We only detect overlap of eGFP expression when co-stained with albumin 




contrast, there was no evidence of coexpression of eGFP and either vimentin or desmin, 
both of which label stellate cells. 
  
3.2.3 scAAV8.miR-29a.eGFP is protective against fibrosis and is associated with 
limited stellate cell activation. 
To test efficacy of the miR-29a virus, we pretreated mice with 2x10
11
 AAV 
genomes, and induced hepatotoxic injury through biweekly injections of CCl4 (Figure 3-
5A).  After 4 weeks of injury, miR-29a expression was significantly downregulated in 
our control group.  However, the group treated with scAAV.miR-29a.eGFP maintained 
expression of miR-29a (Figure 3-5B).  Downregulation of miR-29a in the cohort treated 
with scAAV.eGFP was associated with an increased histological and biochemical 
evidence of fibrosis (Figure 3-5C and 3-5E), and a pathologist blinded to the study 
determined that there was a significant increase in fibrosis between control- and miR-
29a-treated mice (Figure 3-5D).  
We wanted to test the efficacy of our treatment in the context of established 
disease.  Therefore, we pretreated mice with CCl4 for 4 weeks to induce injury before 
systemically delivering 2x10
11
 AAV genomes (Figure 3-6A).  After 8 more weeks of 
CCl4 treatment, we examined miR-29a expression and progression of fibrosis.  Although 
maintenance of miR-29a was lost (Figure 3-6B), eGFP in the miR-29a group was 
detected (unpublished data).  Importantly, fibrosis development was ameliorated in the 
miR-29a group both histologically and biochemically (Figure 3-6C and 3-6E).  




12 weeks (Figure 3-6D), suggesting that mir-29a expression in hepatocytes is protective 
against CCl4-induced liver fibrosis.   
During liver fibrosis, stellate cells morphologically change and produce ECM 
proteins.  Not only did hepatic miR-29a expression limit collagen deposition, but 
treatment of the miR-29a AAV also was associated with fewer alpha-SMA positive cells 
in our prevention and intervention model (Figure 3-7), suggesting that hepatocellular 
maintenance of miR-29a limits activation of stellate cells. 
   
3.2.4 Hepatocytes export miR-29a via exosomes. 
Both in our prevention model and in our intervention model, hepatocellular 
maintenance of miR-29a expression is protective against fibrosis development.  There 
was limited expression of collagen, assessed by histology and protein expression.  Since 
stellate cells and other myofibroblasts make extracellular matrix proteins, we postulated 
that one mechanism of protection could be through exosomal transfer of miR-29a from 
hepatocytes to myofibroblasts.  Recent studies have provided evidence for packaging 
miRNAs into exosomes (Monteclavo et al., 2012; Record et al., 2011), suggesting one 
possible mechanism of non-cell autonomous function.  We transfected pAAV.miR-
29a.eGFP into HuH7 and HeLa cells, and isolated RNA from cells and exosomes.  There 
was a significant increase in cellular and exosomal miR-29a in both cell lines treated with 
pAAV.miR-29a.eGFP (Figure 3-8AB).  While miR-29a increased significantly, we did 
not detect a significant change in other microRNAs that are expressed in both 
compartments, suggesting that overexpression of miR-29a using the AAV vector leads to 





3.2.5 Transfer of miR-29a from hepatocytes to stellate cells limits collagen 
production. 
Since we determined that hepatocellular expression of miR-29a is protective, and 
that hepatic miR-29a is packaged and released from the cell via exosomes, we next asked 
if liver cells transfer miR-29a from one cell type to another.  To test this, we utilized a co-
culture system that mimicked what was seen under fibrotic conditions. Hepatocytes 
treated with either miR-29 inhibitor or pAAV8.miR-29a.eGFP were cultured with LX-2 
cells co-transfected with miR-29 inhibitor and a luciferase vector containing either the 
wild type sequence or mutated sequence of human Col1a1.  Others have confirmed that 
the Col1a1-3’UTR has 3 conserved binding sites for mir-29a (Mendell, unpublished 
data).  After 24 hours, luciferase activity significantly increased when LX-2 cells were 
co-cultured with HuH7 cells treated with miR-29 inhibitor (Figure 3-9).  Conversely, 
overexpressing miR-29a in HuH7 cells significantly decreased luciferase activity in LX-2 
cells, suggesting that modulation of miR-29a in hepatocytes has profound effect on 
collagen production in hepatic stellate cells.   
 
3.3 Discussion 
Using a comprehensive approach to study miRNA changes, we identified that the 
miR-29 family is downregulated in fibrotic whole liver tissue.  Because the miR-29 
family targets many extracellular proteins, including Col1a1, Col3a1, Elastin and 
Fibrillin 1, we hypothesized that decreased miR-29 expression in whole liver could 




cells during liver fibrosis (Roderburg et al., 2011), but its expression and function in 
hepatocytes remained unexplored.  All three mature sequences of miR-29 are 
significantly downregulated after treatment with TGF-beta in primary human 
hepatocytes, suggesting that fibrosis is associated with downregulation of miR-29 in 
hepatocytes.  While others have shown that TGF-beta transcriptionally downregulates 
miR-29a in other settings (Qin et al., 2011; Winbanks et al., 2011), primary miR-29a 
expression does not change during CCl4 induced liver fibrosis, implying that the post-
transcriptional mechanism is hepatocyte-specific.  The actual mechanism of 
hepatocellular post-transcriptional downregulation of miR-29a, however, remains 
unknown but we postulate that it is either due to instability of the mature transcript or 
decrease in miRNA processing. 
scAAV.miR-29a.eGFP did not induce overexpression in vivo, and we hypothesize 
two different possibilities to explain this observation.  First, therapeutic delivery of 
2x10
11
 AAV genomes may not be sufficient to observe overexpression of miR-29a.  
Others have reported detectable miRNA overexpression using the same approach but 
with a five-fold dose increase (Kota et al., 2009).  Given that infection using the same 
control virus at a higher dose resulted in increased eGFP translation and more viral 
genomes, we conclude that this mode of delivery does not limit viral gene expression.  
Second, and more likely, expression of miR-29a in hepatocytes may be tightly regulated.  
Although serial transfections of pAAV.miR-29a.eGFP induce increased expression of 
miR-29a in vitro, uninjured animals treated with scAAV.miR-29a.eGFP have similar 
expression of miR-29a compared to baseline.  Consistent with this hypothesis, we do not 




of scAAV.miR-29a.eGFP (unpublished data).  miR-29a may be tightly regulated such 
that overexpression in hepatocytes is not attainable. 
In this study, we systemically delivered miR-29a using adeno-associated virus 
serotype 8, which has a high tropism for hepatocytes (Grimm et al, 2006; Sands, 2011).  
eGFP expression was only detected when co-staining with albumin, suggesting that 
transduction of AAV8 in the liver is limited predominantly to hepatocytes.  Nonetheless, 
a single injection of 2x10
11
 AAV genomes, which led to about 50% liver cell 
transduction in our model, had a dramatic therapeutic benefit in miR-29a-treated livers 
when comparing histological sections and collagen expression.  This observation was 
consistent not only when pretreating animals with scAAV.miR-29.eGFP but also when 
intervening with scAAV.miR29a.eGFP after induction of fibrosis.  Surprisingly, miR-29a 
was associated with regression of fibrosis in animals that were pretreated with CCl4.   
Genetic deletion of miR-29a in hepatocytes has been associated with increased 
collagen deposition during CCl4 treatment (Kogure et al., 2012).  Consistent with these 
observations, we report for the first time therapeutic benefit through maintenance of miR-
29a expression in hepatocytes.  Systemic delivery of scAAV.miR-29a.eGFP was 
associated with fewer alpha-SMA positive cells.  Because delivery was limited to 
hepatocytes, we hypothesize three potential mechanisms, and we acknowledge that a 
combination of any three are possible.  First, hepatic expression of miR-29a could be 
limiting expression of pro-fibrogenic factors in hepatocytes.  If miR-29a targets genes 
that promote release of proinflammatory cytokines and reactive oxygen species in 
hepatocytes, downstream activation of stellate cells and deposition of collagen would be 




gap junctions between hepatocytes and collagen-producing cells, and others have 
developed methods to follow transfer of miRNAs in this way (Greco et al., 2013; 
Katakowski et al., 2010).  Finally, miRNAs have been reported to be packaged into 
exosomes, and transfer of functional miRNAs through exosomes has been explored in 
other settings (Mittelbrunn et al., 2011; Monteclavo et al., 2012; Valadi et al., 2007).  
Interestingly, both in vivo and in vitro models investigating a non-cell autonomous role 
between hepatocytes and stellate cells have led to the understanding that cross-talk 
between liver-specific cells has a functional benefit (Bhatia et al., 1999; Uyama et al., 
2002; Coulouarn et al., 2012; Benten et al., 2005).  In this study, we investigated if the 
latter possibility could contribute to miR-29a-associated protection in our AAV-treated 
mice.   
We report for the first time that mature miR-29a is released from hepatocytes via 
exosomes.  There is a significant increase in miR-29a in exosomes of hepatocytes (HuH7 
cells) and a second line (HeLa cells) after transfection with pAAV8.miR-29.eGFP.  
Others have reported that members of the miR-29 family, including miR-29a, are 
released in exosomes from cells (Bellingham et al, 2012; Fabbri et al, 2012).  miR-29a 
targets Col1a1 and other extracellular matrix proteins, made predominantly by stellate 
cells in a fibrotic liver.  We confirmed uptake of miR-29a by stellate cells using a co-
culture system transfecting a luciferase plasmid with the 3’UTR of Col1a1 into LX-2 
cells.  The luciferase plasmid is under independent transcriptional control so that 
expression of luciferase would be altered only through transfer of miR-29a from 
hepatocytes to stellate cells.  Since expression of luciferase activity in LX-2 cells cultured 




29a in HuH7 cells was associated with decreased luciferase activity in LX-2 cells, we 
conclude that transfer of miR-29a by hepatocellular exosomes is one mechanism by 
which collagen production in stellate cells is controlled.    
Until now, determining mode of delivery and targeting a specific cell population 
has limited efficacy of viral gene therapy.  In the liver, others targeted collagen-
producing cells using viral systems (Reetz et al., 2013).  Hepatocytes play a central role 
in metabolism, making them a more straightforward target for viral treatment.  Here we 
report a therapeutic benefit of hepatic transduction of miR-29a through one systemic 
injection of an adeno-associated virus.  Our data indicate that this treatment is a powerful 
option to treat toxin-induced liver fibrosis.  While we acknowledge other potential 
mechanisms that could limit collagen deposition, we conclude that one way the liver 
limits collagen production occurs via a non-cell autonomous transfer of miR-29a.   
Although we report robust protection against fibrosis through delivery of miR-
29a, utilization of this AAV system was limiting.  We cannot detect both viral genomes 
and eGFP over the course of 12 weeks of CCl4 treatment.  In order to study the 
observations described in this chapter, we need more sustainable expression of miR-29a 
in the liver.  Chapter 4 will introduce a miR-29a inducible transgenic mouse, which the 
lab will utilize to study these observations more systematically. 
 
3.4 Materials and methods 
3.4.1 Animal Models. 
Animals were housed and experiments were performed with approval by the 




month-old C57BL/6 female mice were given 1 mL/kg of CCl4 (Sigma) intraperitoneally 
biweekly for zero, one, four or eight weeks.  CCl4 was diluted in corn oil at 1:7.  AAV 
was administered at a dose of 2x10
11
 viral genomes per animal by tail vein injection.  At 
the conclusion of the experiments, animals were sacrificed and their livers were perfused 
with cold PBS and harvested. 
 
3.4.2 MicroRNA Array. 
The microRNA array protocol was described in Chapter 2.  Briefly, total mouse 
liver RNA was extracted using a mirVana miRNA Isolation Kit (Ambion, Inc.) according 
to the manufacturer’s protocol.  RNA was DNase treated (DNase I Amplification Grade; 
Invitrogen), and 500 ng RNA was reverse transcribed without pre-amplification using 
Megaplex RT Primers (Rodent Pool A v2.0; ABI) and TaqMan MicroRNA Reverse 
Transcription Kit (ABI), according to the manufacturer’s protocol.  The microarray was 
run on the 7900HT Fast Real-Time PCR System with TaqMan Array Rodent MicroRNA 
A Cards v2.0 (ABI), according to the manufacturer’s protocol. The geometric mean of 
each plate was used for normalization. 
 
3.4.3 Histology. 
Histological slide preparation was described in Chapter 2.  Briefly, whole liver 
tissue was fixed in 10% formalin (Sigma) overnight.  The tissues then were transferred to 
70% ethanol, embedded in paraffin, sectioned and stained with Masson’s trichrome by 




was blinded to AAV and CCl4 treatment details, scored the hepatic fibrosis of each 
animal on a scale of 0-4. 
 
3.4.4 RNA Isolation and qPCR. 
RNA isolation and qPCR were described in Chapter 2.  Briefly, for animal and in 
vitro samples, total RNA was isolated from whole liver tissue using Trizol (Invitrogen) 
according to manufacturer’s protocol.  RNA was DNAse treated (Invitrogen), according 
to the manufacturer’s protocol, and was reverse transcribed using TaqMan MicroRNA 
Reverse Transcription Kit (ABI) with primary or mature miRNA specific primers (ABI) 
and High Capacity Reverse Transcription Kit (ABI) for 18s rRNA and all other non-
miRNAs, all according to the manufacturer’s protocol.  qPCR was performed using pre-
designed TaqMan primers and probes (ABI), according to manufacturer’s protocol.  
qPCR for alpha-SMA, Col1a1, FN1 and PDGF-R-b was performed using Fast SYBR 
Green Master Mix (ABI).  Genes amplified using SYBR Green were normalized to beta-
Actin.  The 2(-delta delta C(T)) Method was used to analyze PCR reactions. 
 
3.4.5 In vitro TGF-beta Treatment of Human Hepatocytes. 
Human hepatocytes (CellzDirect, Durham, NC) were plated on plates coated with 
5ug/ml collagen (Gibco, Grand Island, NY) in serum-rich media (DMEM, 10% FBS, 
15mM Hepes, 10µg/ml gentamycin (Quality Biological, Gaithersburg, MD), 1x ITS 
(Sigma), 1mM dexamethasone (Sigma), and 2mM L-glutamine (Quality Biological)).  




serum starvation, cells were washed, and the same serum-free media plus 5ng/ml TGF-
beta (Roche) was added for 24h, and RNA was collected. 
 
3.4.6 Verification of pAAV8_miR-29a Amplification. 
HEK-293 cells were grown in DMEM supplemented with 10%FBS, penicillin 
and streptomycin.  Serial dilutions of pAAV8_Control_eGFP or pAAV_miR-29a_eGFP 
(cloned by Raghu Chivukula) were transfected with Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol.  Cells were imaged and RNA was isolated 24 
hours after transfection. 
 
3.4.7 Immunostaining. 
Formalin-fixed, paraffin-embedded tissues were sectioned.  5 μm sections were 
transferred to Superfrost/Plus Microscope Slides (Fisher Scientific) and melted onto the 
slide for 30’ at 60°C.  After washing in PBST, samples were blocked with PBS + 5% 
fetal bovine serum (Sigma) and 3% goat serum (Sigma).  Slides were then incubated for 1 
hour at room temperature with anti-albumin (Santa Cruz Biotechnologies, Inc), anti-
vimentin (Millipore, Billerica, MA), anti-desmin (Sigma) anti-α-smooth muscle actin 
conjugated to Cy3 (Sigma), or anti-GFP antibody (Invitrogen).  They were then washed 3 
times in PBST and incubated for one hour at room temperature with one (or two) of the 
following secondary antibodies: Cy3 labeled goat anti-rabbit IgG (GE Healthcare, 
Niskayuna, NY), a Cy3 labeled anti mouse, Cy3 anti-chicken, (both Millipore), or Alexa 
Fluor 488 anti-rabbit (Cell Signaling Technology, Danvers, MA).  Slides were washed 




OR), mounted using Prolong Gold Antifade Reagent (Invitrogen), and subsequently 
imaged under identical conditions. 
 
3.4.8 Collagen Assay. 
Collagen protein expression was determined by Sircol Soluble Collagen Assay 
(Biocolor, Carrickfergus, UK), which was performed according to the manufacturer’s 
protocol.  
 
3.4.9 Blood Chemistry Tests. 
Blood was harvested and blood chemistry tests (LFTs, Albumin) were performed 
by the Department of Comparative Medicine at Johns Hopkins University (Baltimore, 
MD). 
 
3.4.10 In vitro Co-culture Experiment. 
HuH7 and LX-2 cells were grown in DMEM supplemented with 10%FBS, 
penicillin and streptomycin.  Cells were transfected with plasmid DNA or miRIDIAN 
Hairpin Inhibitors (Thermo Fisher Scientific, Waltham, MA) using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol.  24 hours after transfection, cells 
were lysed and cocultured using a 2:1 ratio of HuH7:LX-2 cells.  Lysates were collected 
24 hours after coculturing.   
 






 HeLa, HuH7 and LX-2 cells were plated in triplicate wells of a 24-well 
plate and transfected 24 hours later with 100 ng of the indicated pGL3 3' UTR reporter 
construct and 5 ng of phRL-SV40 (Promega) using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. 48 hours after transfection, cells were lysed and 
assayed for firefly and renilla luciferase activity using the Dual-Luciferase Reporter 
Assay System (Promega). Firefly luciferase activity was normalized to renilla luciferase 
activity for each transfected well. 
 
3.4.12 Exosome Isolation. 
Cells were transfected with Control or miR-29a pAAV as described above.  
Supernatant from five 10cm plates were collected and passed through a 0.22 µm filter.  
Cells were centrifuged at 20,000xg for 30’ at 4 degrees Celsius to remove additional 
cellular debris.  The supernatant was transferred to a new tube and spun by 
ultracentrifugation at 100,000xg for 60’ at 4 degrees Celsius.  From the remaining pellet, 
RNA was isolated using Trizol as previously described.  
 
3.4.13 Statistics. 
A student two-tailed t-test was used to determine significance for in vitro qPCR 
results, collagen assays and pathologist fibrosis scores.  REST 2009 Software was used to 





3.5 Tables: Chapter 3 
Table 3-1. 60 most downregulated miRNAs after 8 weeks of CCl4 treatment in BL/6 
mice.  
Fold change of miRNA expression at 0, 1, 4 and 8 weeks of CCl4 treatment. 
miRNA No CCl4  1 week CCl4  4 weeks CCl4  8 weeks CCl4  
mmu-miR-383 1.00 0.05 0.21 0.06 
mmu-miR-133a 1.00 13.62 0.19 0.22 
mmu-miR-210 1.00 0.35 0.35 0.23 
mmu-miR-802 1.00 0.24 0.09 0.24 
mmu-miR-193 1.00 0.45 0.11 0.32 
mmu-miR-465b-5p 1.00 1.68 0.50 0.36 
mmu-miR-101a 1.00 0.53 0.21 0.38 
rno-miR-345-3p 1.00 0.24 0.18 0.39 
mmu-miR-491 1.00 0.32 0.31 0.41 
mmu-miR-194 1.00 0.44 0.16 0.41 
mmu-miR-107 1.00 0.29 0.14 0.42 
mmu-miR-203 1.00 0.95 0.16 0.44 
rno-miR-339-3p 1.00 1.98 0.61 0.44 
mmu-miR-192 1.00 0.52 0.15 0.45 
mmu-miR-30e 1.00 0.88 0.25 0.45 
mmu-miR-429 1.00 1.33 0.47 0.46 
mmu-miR-16 1.00 1.30 0.29 0.46 
mmu-miR-337-5p 1.00 1.95 0.91 0.46 
mmu-miR-200a 1.00 0.82 0.48 0.49 
mmu-miR-7b 1.00 0.67 1.00 0.50 
mmu-miR-29b 1.00 0.15 0.55 0.50 
mmu-miR-218 1.00 1.72 0.77 0.52 
mmu-miR-687 1.00 0.45 0.53 0.53 
mmu-miR-126-3p 1.00 1.20 0.27 0.53 
mmu-miR-15a 1.00 0.26 0.50 0.54 
mmu-miR-30c 1.00 0.64 0.28 0.54 
mmu-miR-365 1.00 0.35 0.32 0.55 
mmu-miR-872 1.00 0.66 0.71 0.56 
mmu-miR-187 1.00 0.74 0.24 0.56 
mmu-miR-29c 1.00 0.35 0.24 0.57 
mmu-miR-186 1.00 2.33 0.32 0.57 
mmu-miR-30a 1.00 0.33 0.49 0.59 
mmu-let-7g 1.00 0.43 0.33 0.59 
mmu-miR-7a 1.00 0.20 1.02 0.59 
mmu-miR-152 1.00 0.44 0.39 0.59 




mmu-miR-139-5p 1.00 0.81 0.47 0.60 
mmu-miR-27b 1.00 0.27 0.42 0.63 
mmu-miR-126-5p 1.00 0.86 0.31 0.63 
mmu-miR-17 1.00 1.03 0.79 0.64 
mmu-miR-148a 1.00 0.46 0.31 0.64 
mmu-miR-322 1.00 0.68 1.45 0.64 
mmu-miR-200c 1.00 1.30 0.83 0.64 
mmu-miR-30b 1.00 0.60 0.41 0.65 
mmu-miR-24 1.00 1.18 0.50 0.65 
mmu-miR-320 1.00 1.08 0.67 0.65 
mmu-miR-30d 1.00 0.37 0.56 0.66 
mmu-miR-26b 1.00 0.37 0.39 0.66 
mmu-miR-361 1.00 0.46 0.88 0.66 
mmu-miR-467d 1.00 0.34 3.72 0.66 
mmu-miR-32 1.00 0.51 0.37 0.68 
mmu-miR-191 1.00 2.10 0.50 0.68 
mmu-miR-29a 1.00 0.50 0.38 0.69 
mmu-miR-31 1.00 1.47 0.37 0.69 
mmu-miR-542-5p 1.00 0.86 0.60 0.69 
mmu-miR-103 1.00 0.44 0.51 0.71 
mmu-miR-511 1.00 1.14 0.81 0.71 
mmu-miR-338-3p 1.00 0.66 0.74 0.71 
mmu-miR-185 1.00 0.52 0.28 0.71 
mmu-miR-26a 1.00 0.38 0.44 0.72 
 
N=2 in each group.  All groups use geometric mean normalization method, using every 




3.6 Figures: Chapter 3 






A) Representative 10x images of 5 µm liver sections with Maisson trichrome stain.  B) 
Expression of primary miR-29a and miR-29a-c in mice treated with 1, 4 and 8 weeks of 
CCl4. All samples are relative to no CCl4.  C) Expression of primary miR-29a, miR-29a-
c, miR-122 and miR-130a in primary human hepatocytes treated with 5ng/ml TGF-beta 
for 24 hours.  All samples are relative to baseline (t=0h TGF-beta treatment).  Relative 











 A) Schematic representation of scAAV vectors used in this study.  Elongation factor 1 α 
promoter (EF1α), miRNA (shown in hairpin form) and enhanced green fluorescent 
protein (eGFP) are flanked by inverted terminal repeats (ITRs).  B) miR-29a expression 
in scAAV.eGFP- or scAAV.miR29a.eGFP-transfected HEK-293 cells.  Cells were 
transfected with 0 ng, 10 ng, 100 ng or 500 ng of respective vectors.  All samples are 
relative to each 0 ng cohort.  Relative expression was normalized to 18s rRNA.  C) 
Endpoint PCR amplifying gDNA (top) or cDNA (bottom) from whole liver in animals 
injected either with scAAV.eGFP or with scAAV.miR29a.eGFP.  Note the increased size 
in scAAV.miR29a.eGFP due to inclusion of the miR-29a hairpin.  After excision, the 
primers amplify the same size band (bottom).  D) Representative 20x images of HEK-293 












A) Timeline of miR-29a toxicity delivery experiment.  B) Representative 20x Maisson 
trichrome images of 5 µm liver sections 4 weeks after systemic delivery of 
scAAV.eGFP- or scAAV.miR29a.eGFP.  C) Representative 20x immunofluorescent 
images of 5 µm liver sections 4 weeks after systemic delivery of scAAV.eGFP- or 
scAAV.miR29a.eGFP detecting eGFP (red) counterstained with DAPI (blue).  D) 
Expression of primary miR-29a and mature miR-29a in whole liver treated with systemic 
injection of scAAV.  All samples are relative to scAAV.eGFP expression.  Relative 






Figure 3-4. scAAV8.miR-29a.eGFP is predominantly expressed in hepatocytes.  
 
A) Representative 20x immunofluorescent images of 5 µm liver sections 4 weeks after 
systemic delivery of scAAV.eGFP- detecting Albumin (red) and eGFP (green) 
counterstained with DAPI (blue).  B) Representative 20x immunofluorescent images 
detecting Desmin (red) and eGFP (green) counterstained with DAPI (blue).  C) 
Representative 20x immunofluorescent images detecting Vimentin (red) and eGFP 









A) Timeline of miR-29a pretreatment experiment.  B) Expression of primary miR-29a 
and mature miR-29a in whole liver treated with systemic injection of scAAV.  All 
samples are relative to scAAV.eGFP expression.  Relative expression was normalized to 
18s rRNA.  C) Representative 20x Maisson trichrome images of 5 µm liver sections in 
pretreatment group.  D) Fibrosis scores of histological slides of livers from mice in the 
miR-29a pretreatment experiment.  A blinded pathologist scored the histological slides.  
E) Collagen expression in livers from mice in the miR-29a pretreatment experiment.  
Collagen expression was normalized to livers from mice with no scAAV-treatment and 









A) Timeline of miR-29a intervention experiment.  B) Expression of primary miR-29a and 
mature miR-29a in whole liver treated with systemic injection of scAAV.  All samples 
are relative to scAAV.eGFP expression with no CCl4.  Relative expression was 
normalized to 18s rRNA.  C) Representative 20x Maisson trichrome images of 5 µm liver 
sections in intervention experiment.  D) Fibrosis scores of histological slides of livers 
from mice in the miR-29a intervention experiment.  A blinded pathologist scored the 
histological slides.  E) Collagen expression in livers from mice in the miR-29a 
intervention experiment.  Collagen expression was normalized to livers from mice with 4 






 Figure 3-7. scAAV8.miR-29a.eGFP treatment and protection is associated with fewer 
alpha-SMA-positive cells.  
 
A) Representative 20x immunofluorescent images of 5 µm liver sections 4- and 12-weeks 
after systemic delivery of scAAV.eGFP- detecting alpha-SMA (red) counterstained with 










A) Expression of miR-29a, miR-29c, miR-16 and miR-130a in cells and exosomes of 
HuH7 cells transfected with control or miR-29a pAAV. B) Expression of miR-29a, miR-
29c, miR-16 and miR-130a in cells and exosomes of HeLa cells transfected with control 
or miR-29a pAAV.  All miRNA expression is relative to cells or exosomes treated with 




Figure 3-9. Inhibition or overexpression of miR-29a in hepatocytes affects collagen 
expression in co-cultured stellate cells. 
 
A) Luciferase expression of Luc_WT-Col1a1-3’UTR or Luc_Mutant-Col1a1-3’UTR in 
co-cultured HuH7 and LX-2 cells.  All LX-2 cells were treated with 30 nM miR-29 
cocktail inhibitor.  HuH7 cells were transfected with 30 nM scrambled or miR29 cocktail 
inhibitor, or with control or miR-29a pAAV8 vector. Expression of luciferase was 






4. CHAPTER 4. GENERATION OF AN INDUCIBLE TRANSGENIC MIR-29A 
MOUSE 
4.1 Introduction. 
In Chapter 3, expression of miR-29a using an adeno-associated virus provided a 
dramatic therapeutic benefit to mice treated with carbon tetrachloride (CCl4).  However, 
miR-29a expression was not sustainable because repeated insults caused hepatic injury 
and loss of virus expression.  After 12 weeks of CCl4 treatment, mice treated with 
scAAV.miR-29a.eGFP lost most expression of eGFP and nearly all viral genomes.  This 
chapter describes the creation of a miR-29a inducible transgenic mouse using a published 
approach (Beard et al., 2006).  This mouse line will have consistent, cell-specific and 
inducible expression to study miR-29a using not only our CCl4 model but also using 
other clinically relevant models.  Importantly, we will use this transgenic mouse line to 
study the non-cell autonomous phenomenon presented in Chapter 3. 
 
4.2 Construct of an inducible miR-29a transgenic mouse. 
We inserted the miR-29a hairpin in the 3’UTR of eGFP.  To test expression of 
this construct, we inserted this sequence, eGFP.miR-29a.polyA, into pcDNA3.   GFP was 
readily detectable in HeLa cells after transfection (Figure 4-1A) and there was an 
increase in expression of miR-29a (Figure 4-1B).   Having functional evidence that our 
construct expressed both eGFP and miR-29a, we inserted loxp-stop-loxp.eGFP.miR-
29a.polyA into pBS31_tetO, and created a transgenic mouse line with expression of this 
inducible transgene downstream of Col1a1 (Figure 4-2).  eGFP and miR-29a are 




(LSL).  Crossing our transgenic line to a Cre-specific driver line excises LSL and 
removes transcriptional inhibition downstream of the tetO promoter.  Finally, from the 
ROSA26 locus, KH2* Cells express a tet-on transactivator, rtTA, which allows for 
controlled transcription of eGFP.miR-29a only when mice are treated with doxycycline.  
Using this method, miR-29a has cell-specific and temporal expression which will allow 
us to study cell-specific miR-29a targets. 
 
4.3 Detection and expression of an inducible miR-29a transgenic mouse. 
To examine miR-29a expression in our inducible transgenic mouse, we crossed 
miR-29a/+; rtTA/+ animals to Albumin:Cre/+ animals.  After genotyping for each 
transgene (Figure 4-3A), animals were given doxycycline.  While there was no increase 
in miR-29a after 7 days (Figure 4-3B), we saw hepatocellular expression of eGFP (Figure 
4-3C).  Importantly, samples positive for Albumin:Cre excised loxp-stop-loxp, and 
transgenic miR-29a was detected by endpoint PCR (Figure 4-3A).   
 
4.4 Future directions 
While we have functional evidence of expression of miR-29a, our transgenic 
mouse could be fine tuned to facilitate easier husbandry and increase expression.  First, 
we have interbred miR-29/+; rtTA/+ mice to create double homozygous transgenic mice, 
allowing for more straightforward genotyping after crossing to different cre-driver lines.  
Second, we will utilize ubiquitous cre-driver lines that will ensure excision of LSL in 
every cell type.  Finally, others have engineered a more potent tet-on transactivator (Das 




After successful husbandry, we plan to utilize this mouse in different liver fibrosis 
studies, including a systematic investigation into the non-cell autonomous phenomenon 
that we observe in miR-29a AAV-treated mice.  Sustained expression of miR-29a in 
hepatocytes and other liver cells would allow for miR-29a to be studied more 
systematically.  Interestingly, miR-29a was not overexpressed in our Alb:cre triple 
transgenic baseline model, suggesting tight regulation of hepatocellular expression that is 
consistent with our AAV8 model.  Our lab will pursue other liver specific studies, 
including isolation of miR-29a transgenic cells and identification of miR-29a targets 
using methods to isolate and sequence targets. 
 
4.5 Materials and methods 
4.5.1 Molecular cloning. 
Loxp-stop-loxp.eGFP.miR-29a was inserted into pBS31_tetO at the EcoRI site 
(Thermo Scientific Open Biosystems, Pittsburgh, PA).  eGFP.miR-29a was cloned into 
pcDNA3 at the XhoI site.  Clones positive by digest were confirmed using Sanger 
sequencing (Sequencing Facility, Johns Hopkins University, Baltimore, MD).  pDNA 
was transfected into HeLa cells using Lipofectamine 2000 using the manufacturer’s 
protocol.  
 
4.5.2 Generation of an inducible miR-29a transgenic mouse line. 
Animals were housed and experiments were performed with approval by the 
Johns Hopkins School of Medicine Animal Care and Use Committee. 




cells using the manufacturer’s protocol.  Clones were sequenced, and positive clones 
were injected into WT C57BL/6 mice blastocysts.  Founders were identified though 
outcrossing.  Additional generations were outcrossed and genotyped for miR-29a and 
rtTA.  Positively transgenic animals were given 2mg/ml doxycycline hyclate (Sigma-
Aldrich) in water supplemented with 10mg/ml sucrose. 
 
4.5.3 gDNA isolation, RNA isolation and PCR. 
Mouse tails were excised in digested in Proteinase K (Invitrogen) overnight at 
56ºC.  The next day, gDNA was extracted using 5M NaCl, 100% EtOH and washed with 
70% EtOH.  gDNA was resuspended in H2O and used as template.  DreamTaq 2x Master 
Mix (Fermentas) was used for endpoint PCR reactions using the manufacturer’s protocol. 
RNA was isolated from HeLa cells or whole liver tissue, and qPCR was 
performed as described in Chapters 2 and 3. RNA isolation and qPCR were described in 
Chapter 2.  Briefly, total RNA was isolated using Trizol (Invitrogen) according to 
manufacturer’s protocol.  RNA was DNAse treated (Invitrogen), according to the 
manufacturer’s protocol, and was reverse transcribed using TaqMan MicroRNA Reverse 
Transcription Kit (ABI) with primary or mature miRNA specific primers (ABI) and High 
Capacity Reverse Transcription Kit (ABI) for 18s rRNA and all other non-miRNAs, all 
according to the manufacturer’s protocol.  qPCR was performed using pre-designed 
TaqMan primers and probes (ABI), according to manufacturer’s protocol.  miR-29a was 







Liver was excised, rinsed in cold PBS and fixed in 4% paraformaldehyde 
(Electron Microscopy Sciences, Hatfield, PA) overnight.  The next day, tissue was 
embedded in OCT and snap-frozen in liquid nitrogen.  5 µm sections were cut and 
stained for eGFP using the same protocol described in Chapter 3.  Briefly, samples were 
blocked with PBS + 5% fetal bovine serum (Sigma) and 3% goat serum (Sigma).  Slides 
were then incubated for 1 hour at room temperature with anti-GFP antibody (Invitrogen).  
They were then washed 3 times in PBST and incubated for one hour at room temperature 
with Cy3 labeled goat anti-rabbit IgG (GE Healthcare, Niskayuna, NY).  Slides were 
washed three times in PBST and counterstained with Hoechst 33258 (Molecular Probes, 
Eugene, OR), mounted using Prolong Gold Antifade Reagent (Invitrogen), and 






4.6 Figures: Chapter 4 
Figure 4-1. eGFP and miR-29a expression in HeLa cells transfected with eGFP- 
miR29.   
 
A) Representative 20x fluorescent image detecting eGFP (green) expression. B) 
Expression of miR-29a in HeLa cells transfected with pcDNA3_eGFP_miR-29a-polyA. 
miRNA expression is relative to no plasmid mock transfection.  Relative expression was 




Figure 4-2. Inducible miR-29a construct.  
 
The miR-29a transgene was inserted 1.6kb downstream of Col1a1 on 
chromosome 11 using FRT (Flp Recognition Target) Sites.  The constuct consisted of a 
Tet-regulatable element (TRE), loxp-stop-loxp (LSL), enhanced green fluorescent protein 





Figure 4-3. Detection of transgenic miR-29a and eGFP in miR-29a animal using an 
albumin specific cre driver line. 
 
A) Endpoint PCR detecting miR-29a, rtTA, IL2 (an internal control to test gDNA 
quality), Cre, and deletion of loxp-stop-loxp using gDNA as template.  The last PCR uses 
RT-DNA as template and amplifies miR-29a.  B) Expression of miR-29a from whole 
liver in animals with and without Albumin:Cre. miRNA expression is relative to no 
albumin:cre.  Relative expression was normalized to 18s rRNA.  C) Representative 40x 
immunofluorescent images of 5 µm liver sections detecting eGFP (red) counterstained 
with DAPI (blue) after 7 days of doxycycline treatment.  Animals were given 2mg/ml 





5. CHAPTER 5. CONCLUDING REMARKS 
 
5.1 Importance of studying cell-specific microRNA expression  
We set out to survey miRNA dysregulation during liver fibrosis in order to 
identify unknown targets and novel mechanisms.  As members not only of the Human 
Genetics Program but also of the Department of Surgery, our interest predominantly 
focuses on understanding changes in gene expression during solid organ dysfunction.  By 
studying gene expression dysregulation during liver fibrosis, we hypothesized that we 
could identify novel markers to predict fibrosis progression and even develop 
individualized treatment options for patients who either have spent time on a wait list or 
have received an organ.    
We identified two families of miRNAs that are dysregulated during organ 
fibrosis.  The miR-214/199 family is upregulated during liver fibrosis, and the miR-29 
family is downregulated.  Nevertheless, through identification of targets using in silico 
predictions and in vitro validation, we discovered that both of these families have 
members whose expression is protective during fibrosis.   
We focused our efforts on globally examining microRNA changes during 
progression of liver fibrosis.  By examining whole tissue using a low density array, we 
successfully surveyed expression of over 350 miRNAs as fibrosis developed.  However, 
it became increasingly evident that studying miRNA changes in a complex organ with a 
heterogeneous cell population could cause identification of false positives and omission 
of cell-specific miRNA changes.  During fibrosis, immune cells infiltrate and 




When examining miRNA expression in fibrotic liver tissue, an increase, for example in 
stellate cells, could cause an increase in miRNA expression if that miRNA is stellate cell-
specific.  Single cell isolation, promoter-specific transgenic lines, co-
immunohistochemistry and/or in vitro investigation of miRNA dynamics need to be 
utilized when observing changes in expression of whole tissue.   The projects described 
in this thesis elucidate expression and function of miR-214-5p and miR-29a in different 
liver cell populations and should serve as examples of how to examine miRNA 
expression systematically in complex tissue.  miR-214-5p expression predominates 
parenchymal cells, including stellate cells.  While miR-29a is highly expressed in a 
variety of cell types, it functions differently in each cell type.  By identifying cell-specific 
expression, researchers can pinpoint and test targets more efficiently.  
In Chapter 3, we deliver miR-29a to hepatocytes and report functional prevention 
and reversal of fibrosis, which was associated with a decrease in stellate cell activation. 
miRNAs target and regulate genes often times in the same networks and pathways. This 
study has suggested that modulation of a single miRNA can have profound implications 
on solid organ gene expression non-cell autonomously.  Future studies indentifying 
miRNA changes and elucidating functional targets in a pathophysiological setting would 
lead to development of specific biomarkers and therapies. 
 
5.2 The miR-214/199 family in liver fibrosis: additional opportunities on the 
horizon 
In Chapter 2, I report overexpression of the miR-214/199 family during liver 




this miRNA family.  We identified a negative feedback loop between miR-214-5p and 
Twist1, and provided evidence that this feedback loop limits proliferation, migration and 
ECM production in hepatic stellate cells.   
miR-214-5p is one of five unique sequences in the miR-214/199 family, and all 
five mature sequences are processed in hepatic stellate cells.  Other members of this 
family have been implicated in different settings of fibrosis, and evolutionarily conserved 
families that are upregulated in the same setting could target similar networks and 
pathways.  For example, miR-214-3p has been reported to target Plexin-B1 to limit 
proliferation of cervical cancer cells, and miR-199a overexpression in hepatocellular 
carcinoma is associated with limited HIF1A and phospho-AKT, which promotes growth 
and migration (Qiang et al., 2011; Jia et al., 2012).  Future studies to identify targets of 
these miRNAs specifically in stellate cells would uncover if other members of the miR-
214/199 family target similar myofibroblast-specific gene networks or pathways as miR-
214-5p and Twist1.   
While there are five reports mature sequences in this microRNA family, our 
studies have identified a second mature strand for miR-214-5p.  Given the potential for 
the impact of discovering a microRNA hairpin that processes more than two mature 
strands, elucidation of rno-miR-214-5p and any potential targets represents an extremely 
interesting project.  Consistent with other mature sequences in this hairpin, rno-miR-214-
5p is significantly upregulated in during liver fibrosis.  Since all miRNAs in DNM3os are 
under the same transcriptional control, one would hypothesize that there are functional 




Our in vitro studies suggest that miR-214-5p is a potent regulator of stellate cell 
activation.  Given these observations, an in vivo model knocking out miR-214 in the liver 
would assess its protective function in liver fibrosis.  Alternatively, in vivo mimics or 
viral vectors overexpressing miR-214 could be protective against fibrosis by limiting 
Twist1 and other pro-fibrotic genes. 
In this study, we systematically examined expression and function of miR-214 in 
activated nonparenchymal cells.  One of the most interesting observations we 
encountered is that miR-214-3p and miR-199a-3p increase mildly over recurrence of 
HCV of a newly transplanted graft.  Although samples like these are difficult to obtain, 
we should slowly grow our database of human samples to correlate our observed rodent 
and in vitro phenotypes with the human condition.  Additionally, examining cell specific 
expression of the miR-214/199 family in human samples using in situ hybridization 
techniques would confirm upregulation of this miRNA family in nonparenchymal cells. 
 
5.3 The miR-29 family: additional opportunities on the horizon 
In Chapter 3, I described a project in which we systemically delivered miR-29a to 
the liver and ameliorated a fibrotic phenotype.  miR-29a targets many ECM proteins, 
including Co1la1.  While we only transduce hepatocytes, we see dramatic therapeutic 
benefit that includes decrease in collagen accumulation.  We elucidate a possible non 
cell-autonomous mechanism in which miR-29a is packaged into exosomes and received 
by stellate cells, where collagen translation is inhibited.    
We created an inducible miR-29a transgenic mouse to address a few problems.  




This non-integrating vector is lost during repeated hepatocellular divisions.  Second, we 
could timely and spatially regulate expression of miR-29a in this system through the use 
of Cre-specific driver lines and treatment with doxycycline.  Finally, isolation of miR-
29a-positive cells lend insight into cell autonomous targets that could limit release of 
proinflammatory factors that activate stellate cell activation and collagen production. 
The use of AAV serotype 8 to deliver miR-29a revealed the possibility for new 
mechanisms of protection.  Hepatocellular miR-29a could limit release of pro-fibrotic 
cytokines and other signals that activate myofibroblasts.  However, this mechanism 
remains unclear.  To address this possibility, our lab is utilizing a protocol in which we 
treat hepatocytes and stellate cells with a biotin-tagged miR-29a oligo.  By fixing 
transfected cells and isolating miR-29a bound 3’UTR targets using an avidin antibody, 
we can identify targets that would limit non-cell autonomous activation of stellate cells. 
Our ultimate goal in this project is to identify novel targets and develop a 
sustainable therapy for protection against liver fibrosis. miR-29a is a potent regulator of 
ECM protein, and determining a way to deliver miR-29a to any solid organ, especially 
the liver, would limit development of fibrosis.  Identification and testing of sustainable 
packaging systems which deliver miR-29a to specific cell populations would allow for 
enhanced protection against developing liver fibrosis.   
 
5.4 Concluding remarks 
The work in this thesis has identified two novel pathways in which microRNAs 




expressed in this pathologic setting.  Using both in vitro and in vivo models, we suggest 
that these two miRNA families are important negative regulators of organ fibrosis.   
In both studies, we provide evidence of cell specific expression of miR-214-5p 
and miR-29a, and we identify two mechanisms by which liver fibrosis is ameliorated.  
Future directions in this field should focus on identifying cell specific expression of 
miRNAs using in vitro gene expression manipulation, in situ hybridization techniques 
and transgenic models.  Using these approaches, the field will more rapidly identify and 
validate mRNA targets in order to develop diagnostic markers and gene therapies to treat 
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Appendix 1. Cloning and qPCR Primers. 
Cloning Primers Primer Sequence 
Hsa-miR-214 Fw 5’ GCC GGG CCG GCC TCG AGG ATC CTG TA 3’ 
Hsa-miR-214 Rev 5’ CGG CGG CCG GCC TCG AGC TAG CAT T 3’ 
Hsa-miR-199a Fw 5’ GCC GGG CCG GCC TCG AGG ATC CAG T 3’ 
Hsa-miR-199a Rev  5’ CGG CGG CCG GCC TCG AGC TAG CGC G 3’ 
Hsa-Twist1 3’UTR Fw 5’ CGC CTC TAG AGC TGG ATA ACT AAA AAT 3’ 
Hsa-Twist1 3’UTR Rev 5’GGC GTC TAG ACA CAA ACA ACT GTT C 3’ 
Hsa-Twist1 Fw 5’ GCG CGG AAT TCA TGA TGC AGG ACG TGT CCA GC 3’ 
Hsa-Twist1 Rev 5’ CGC GCG AAT TCC TAG TGG GAC GCG GAC ATG G 3’ 
BsrGI miR-29a Tg Mus Fw 
5’ GCG GTG TAC AAG TAA GAG CCC AAT GTA TGC TGG 
3’ 
MluI miR-29a Tg Mus Rev 5’ CGG CAC GCG TTG CAT TAT TGC TTT GCA TTT G 3’ 
XhoI eGFP_mir29 Fw 5’ GCG CGG GAT CCA TGG TGA GCA AGG 3’ 
XhoI eGFP_mir29 Rev 5’ CGG CCC TCG AGA AAT TCC AAC ACA CTA TTG C 3’ 
 
qPCR Primer  Primer Sequence 
Hsa-Alpha-SMA Fw 5’ CTG TTC CAG CCA TCC TTC AT 3’ 
Hsa-Alpha-SMA Rev 5’ CCG TGA TCT CCT TCT GCA TT 3’ 
Hsa-Col1a1 Fw 5’ CAA GAG GAA GGC CAA GTC GAG G 3’ 
Hsa-Col1a1 Rev 5’ CGT TGT CGC AGA CGC AGA T 3’ 
Hsa-CTGF Fw 5’ CCT GGT CCA GAC CAC AGA GT 3’ 
Hsa-CTGF Rev 5’ TGG AGA TTT TGG GAG TAC GG 3’ 
Hsa-FN1 Fw 5’ GAA CTA TGA TGC CGA CCA GAA 3’ 
Hsa-FN1 Rev 5’ GGT TGT GCA GAT TTC CTC GT 3’ 
Hsa-PDGF-R-beta Fw 5’ CGC AGC AGT GAG AAG CAA GC 3’ 
Hsa-PDGF-R-beta Rev 5’ TAG TCC ACC AGG TCT CCG TAG C 3’ 
Hsa-TGF-beta Fw 5’ AGC GAC TCG CCA GAG TGG TTA 3’ 
Hsa-TGF-beta Rev 5’ GCA GTG TGT TAT CCC TGC TGT CA 3’ 
Hsa-MMP9 Fw 5' TCG AAC TTT GAC AGC GAC AAG AA 3’ 
Hsa-MMP9 Rev 5’ TCA GTG AAG CGG TAC ATA GGG TAC A 3’ 
Hsa-MMP2 Fw 5’ TGA CAT CAA GGG CAT TCA GGA G 3’ 
Hsa-MMP2 Rev 5’ TCT GAG CGA TGC CAT CAA ATA CA 3’ 
Hsa-TIMP1 Fw 5’ GGA TAC TTC CAC AGG TCC CAC AA 3’ 
Hsa-TIMP1 Rev 5’ CTG CAG GTA GTG ATG TGC AAG AGT C 3’ 
Hsa-Twist1 Fw 5’ CAT CGA CTT CCT CTA CCA GGT C 3’ 
Hsa-Twist1 Rev 5’ TGT CCA TTT TCT CCT TCT CTG GA 3’ 
Hsa-E-cadherin Fw 5’ GGA TGT GCT GGA TGT GAA TG 3’ 
Hsa-E-cadherin Rev 5’ CAC ATC AGA CAG GAT CAG CAG AA 3’ 




Hsa-N-cadherin Rev 5’ TCA GTC ATC ACC TCC ACC AT 3’ 
Hsa-Vimentin Fw 5’ GAG AAC TTT GCC GTT GAA GC 3’ 
Hsa-Vimentin Rev 5’ TCC AGC AGC TTC CTG TAG GT 3’ 
Hsa-Zeb1 Fw 5’ GC ACCT GAA GAG GAC CAG AG 3’ 
Hsa-Zeb1 Rev 5’ TGC ATC TGG TGT TCC ATT TT 3’ 
Hsa-Zeb2 Fw 5’ CAA GAG GCG CAA ACA AGC 3’ 
Hsa-Zeb2 Rev 5’ GGT TGG CAA TAC CGT CAT 3’ 
Rno-DNM1 Fw 5’ CCG CCG CAA CCA TGG GCA AC 3’ 
Rno-DNM1 Rev 5’ GGC AAG AAG TCC CTG CCC ACG AA 3’ 
Rno-DNM2 Fw 5’ GAG GCG GGC ACC ATG GGC ACC 3’ 
Rno-DNM2 Rev 5’ GGA AGG AAG TCC CGG CCC ACG 3’ 
Rno-DMN3 Fw 5’ GGA AGA ACT GAT CCC TCT GGT G 3’ 
Rno-DNM3 Rev 5’ CAC GAA GTT CTC GAG CAC TGA GC 3’ 
Hsa-Beta-Actin Fw  5’ ACC TTC TAC AAT GAG CTG CG 3’ 
Hsa-Beta-Actin Rev 5’ CCT GGA TAG CCA CGT ACA TGG 3’ 
Rno-Beta-Actin 5’ CCC ATT GAA CAC GGC ATT 3’ 
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